Lars Wallentin

Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

Wallentin, Lars; Lindbäck, Johan; Hijazi, Ziad; Oldgren, Jonas et al.

Ingår i Journal of the American College of Cardiology, 2025

• DOI för Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Not Receiving Oral Anticoagulation

Aulin, Julia; Sjölin, Karl; Lindbäck, Johan; Benz, Alexander P. et al.

Ingår i Journal of the American Heart Association, 2025

• DOI för Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Not Receiving Oral Anticoagulation
• Ladda ner fulltext (pdf) av Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Not Receiving Oral Anticoagulation

Standardised and hierarchically classified heart failure and complementary disease monitoring outcome measures: european Unified Registries for heart Care evaluation and randomised trials (EuroHeart).

Bhatty, Asad; Wilkinson, Chris; Batra, Gorav; Aktaa, Suleman et al.

Ingår i European Heart Journal - Quality of Care and Clinical Outcomes, 2024

• DOI för Standardised and hierarchically classified heart failure and complementary disease monitoring outcome measures: european Unified Registries for heart Care evaluation and randomised trials (EuroHeart).

Switching to Direct Anticoagulation or Continued Vitamin-K Antagonists in Frail Patients With Atrial Fibrillation in Whom Vitamin-K Antagonists Are Tolerated?

Wallentin, Lars; Giugliano, Robert P.

Ingår i Circulation, s. 290-292, 2024

• DOI för Switching to Direct Anticoagulation or Continued Vitamin-K Antagonists in Frail Patients With Atrial Fibrillation in Whom Vitamin-K Antagonists Are Tolerated?

Temporal biomarker concentration patterns during the early course of acute coronary syndrome

Eggers, Kai M.; Batra, Gorav; Lindahl, Bertil; Lakic, Tatevik et al.

Ingår i Clinical Chemistry and Laboratory Medicine, s. 1167-1176, 2024

• DOI för Temporal biomarker concentration patterns during the early course of acute coronary syndrome
• Ladda ner fulltext (pdf) av Temporal biomarker concentration patterns during the early course of acute coronary syndrome

Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

Wallentin, Lars; Lindbäck, Johan; Hijazi, Ziad; Oldgren, Jonas et al.

Ingår i Journal of the American College of Cardiology, 2025

• DOI för Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Not Receiving Oral Anticoagulation

Aulin, Julia; Sjölin, Karl; Lindbäck, Johan; Benz, Alexander P. et al.

Ingår i Journal of the American Heart Association, 2025

• DOI för Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Not Receiving Oral Anticoagulation
• Ladda ner fulltext (pdf) av Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Not Receiving Oral Anticoagulation

Standardised and hierarchically classified heart failure and complementary disease monitoring outcome measures: european Unified Registries for heart Care evaluation and randomised trials (EuroHeart).

Bhatty, Asad; Wilkinson, Chris; Batra, Gorav; Aktaa, Suleman et al.

Ingår i European Heart Journal - Quality of Care and Clinical Outcomes, 2024

• DOI för Standardised and hierarchically classified heart failure and complementary disease monitoring outcome measures: european Unified Registries for heart Care evaluation and randomised trials (EuroHeart).

Switching to Direct Anticoagulation or Continued Vitamin-K Antagonists in Frail Patients With Atrial Fibrillation in Whom Vitamin-K Antagonists Are Tolerated?

Wallentin, Lars; Giugliano, Robert P.

Ingår i Circulation, s. 290-292, 2024

• DOI för Switching to Direct Anticoagulation or Continued Vitamin-K Antagonists in Frail Patients With Atrial Fibrillation in Whom Vitamin-K Antagonists Are Tolerated?

Temporal biomarker concentration patterns during the early course of acute coronary syndrome

Eggers, Kai M.; Batra, Gorav; Lindahl, Bertil; Lakic, Tatevik et al.

Ingår i Clinical Chemistry and Laboratory Medicine, s. 1167-1176, 2024

• DOI för Temporal biomarker concentration patterns during the early course of acute coronary syndrome
• Ladda ner fulltext (pdf) av Temporal biomarker concentration patterns during the early course of acute coronary syndrome

Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation

Patel, Siddharth M.; Braunwald, Eugene; Steffel, Jan; Boriani, Giuseppe et al.

Ingår i Circulation, s. 932-943, 2024

• DOI för Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation

Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation

Aulin, Julia; Sjölin, Karl; Lindbäck, Johan; Benz, Alexander P et al.

Ingår i Circulation, s. 1090-1100, 2024

• DOI för Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation

Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF

Johnson, Linda S.; Benz, Alexander P.; Shoamanesh, Ashkan; Eikelboom, John W. et al.

Ingår i Journal of the American Heart Association, 2024

• DOI för Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF
• Ladda ner fulltext (pdf) av Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF

Optimizing warfarin dosing for patients with atrial fibrillation using machine learning

Petch, Jeremy; Nelson, Walter; Wu, Mary; Ghassemi, Marzyeh et al.

Ingår i Scientific Reports, 2024

• DOI för Optimizing warfarin dosing for patients with atrial fibrillation using machine learning
• Ladda ner fulltext (pdf) av Optimizing warfarin dosing for patients with atrial fibrillation using machine learning

Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Gkarmiris, Konstantinos I.; Lindbäck, Johan; Alexander, John H.; Granger, Christopher B. et al.

Ingår i Journal of the American Heart Association, 2024

• DOI för Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial
• Ladda ner fulltext (pdf) av Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Cardiometabolic Co-morbidity Burden and Circulating Biomarkers in Patients With Chronic Coronary Disease in the ISCHEMIA Trials

Hamo, Carine E.; Liu, Richard; Wu, Wenbo; Anthopolos, Rebecca et al.

Ingår i American Journal of Cardiology, s. 118-124, 2024

• DOI för Cardiometabolic Co-morbidity Burden and Circulating Biomarkers in Patients With Chronic Coronary Disease in the ISCHEMIA Trials

Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF

Haller, Paul M.; Jarolim, Petr; Palazzolo, Michael G.; Bellavia, Andrea et al.

Ingår i Journal of the American College of Cardiology, s. 1528-1540, 2024

• DOI för Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF

Associations between psychosocial burden and prognostic biomarkers in patients with chronic coronary syndrome: a STABILITY substudy.

Wassberg, Charlotte; Batra, Gorav; Hadziosmanovic, Nermin; Hagström, Emil et al.

Ingår i European Journal of Preventive Cardiology, 2024

• DOI för Associations between psychosocial burden and prognostic biomarkers in patients with chronic coronary syndrome: a STABILITY substudy.

Cohort profile: the European Unified Registries On Heart Care Evaluation and Randomized Trials (EuroHeart)-acute coronary syndrome and percutaneous coronary intervention

Bhatty, Asad; Wilkinson, Chris; Batra, Gorav; Alfredsson, Joakim et al.

Ingår i European Heart Journal - Quality of Care and Clinical Outcomes, s. 386-390, 2024

• DOI för Cohort profile: the European Unified Registries On Heart Care Evaluation and Randomized Trials (EuroHeart)-acute coronary syndrome and percutaneous coronary intervention

Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Wilkinson, Chris; Bhatty, Asad; Batra, Gorav; Aktaa, Suleman et al.

Ingår i European Heart Journal, s. 190-214, 2024

• DOI för Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)
• Ladda ner fulltext (pdf) av Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets

Zhao, Jing Hua; Stacey, David; Eriksson, Niclas; Macdonald-Dunlop, Erin et al.

Ingår i Nature Immunology, s. 1540-1551, 2023

• DOI för Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets
• Ladda ner fulltext (pdf) av Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets

Real world evidence: Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency

Szymanski, Piotr; Weidinger, Franz; Lordereau-Richard, Isabelle; Himmelmann, Anders et al.

Ingår i European Heart Journal - Quality of Care and Clinical Outcomes, s. 109-118, 2023

• DOI för Real world evidence: Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency

Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores

Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas; Benz, Alexander P. et al.

Ingår i American Heart Journal, s. 55-63, 2023

• DOI för Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores
• Ladda ner fulltext (pdf) av Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores

Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation

Benz, Alexander P.; Hohnloser, Stefan H.; Eikelboom, John W.; Carnicelli, Anthony P. et al.

Ingår i European Heart Journal, s. 1807-1814, 2023

• DOI för Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation

Vascular endothelial growth factor-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular disease

Davidsson, Pia; Eketjall, Susanna; Eriksson, Niclas; Walentinsson, Anna et al.

Ingår i Cardiovascular Research, s. 1596-1605, 2023

• DOI för Vascular endothelial growth factor-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular disease

Heart rate and death and hospitalization for heart failure in patients with persistent or permanent atrial fibrillation: Insights from the ARISTOTLE trial

Vinereanu, Dragos; Wojdyla, Daniel M.; Alexander, John H.; Lopes, Renato D. et al.

Ingår i American Heart Journal, s. 132-136, 2023

• DOI för Heart rate and death and hospitalization for heart failure in patients with persistent or permanent atrial fibrillation: Insights from the ARISTOTLE trial

Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries: Results From the PLATO Trial

Hjort, Marcus; Eggers, Kai M.; Ghukasyan Lakic, Tatevik; Lindbäck, Johan et al.

Ingår i Journal of the American Heart Association, 2023

• DOI för Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries: Results From the PLATO Trial
• Ladda ner fulltext (pdf) av Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries: Results From the PLATO Trial

Data standards for transcatheter aortic valve implantation: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart).

Aktaa, Suleman; Batra, Gorav; James, Stefan; Blackman, Daniel J et al.

Ingår i European Heart Journal - Quality of Care and Clinical Outcomes, s. 529-536, 2023

• DOI för Data standards for transcatheter aortic valve implantation: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart).

Data standards for atrial fibrillation/flutter and catheter ablation: The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Batra, Gorav; Aktaa, Suleman; Camm, A. John; Costa, Francisco et al.

Ingår i European Heart Journal - Quality of Care and Clinical Outcomes, s. 609-620, 2023

• DOI för Data standards for atrial fibrillation/flutter and catheter ablation: The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)
• Ladda ner fulltext (pdf) av Data standards for atrial fibrillation/flutter and catheter ablation: The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF

Harrington, Josephine; Carnicelli, Anthony P.; Hua, Kaiyuan; Wallentin, Lars et al.

Ingår i Circulation, s. 1748-1757, 2023

• DOI för Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF

Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation

Benz, Alexander P.; Hijazi, Ziad; Lindbäck, Johan; Connolly, Stuart J. et al.

Ingår i Europace, 2023

• DOI för Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation
• Ladda ner fulltext (pdf) av Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation

Excessive daytime sleepiness, morning tiredness, and prognostic biomarkers in patients with chronic coronary syndrome

Olszowka, Maciej; Hagström, Emil; Hadziosmanovic, Nermin; Ljunggren, Mirjam et al.

Ingår i International Journal of Cardiology, 2023

• DOI för Excessive daytime sleepiness, morning tiredness, and prognostic biomarkers in patients with chronic coronary syndrome
• Ladda ner fulltext (pdf) av Excessive daytime sleepiness, morning tiredness, and prognostic biomarkers in patients with chronic coronary syndrome

Morbidity and Mortality Associated With Heart Failure in Acute Coronary Syndrome: A Pooled Analysis of 4 Clinical Trials

Goodwin, Nathan P.; Clare, Robert M.; Harrington, Josephine L.; Badjatiya, Anish et al.

Ingår i Journal of Cardiac Failure, s. 1603-1614, 2023

• DOI för Morbidity and Mortality Associated With Heart Failure in Acute Coronary Syndrome: A Pooled Analysis of 4 Clinical Trials

Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21)

Siegbahn, Agneta; Eriksson, Niclas; Assarsson, Erika; Lundberg, Martin et al.

Ingår i PLOS ONE, 2023

• DOI för Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21)
• Ladda ner fulltext (pdf) av Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21)

Biomarkers and cardiovascular events in patients with stable coronary disease in the ISCHEMIA Trials

Newman, Jonathan D.; Anthopolos, Rebecca; Ruggles, Kelly V.; Cornwell, Macintosh et al.

Ingår i American Heart Journal, s. 61-73, 2023

• DOI för Biomarkers and cardiovascular events in patients with stable coronary disease in the ISCHEMIA Trials

Author Correction: Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.

Zhao, Jing Hua; Stacey, David; Eriksson, Niclas; Macdonald-Dunlop, Erin et al.

Ingår i Nature Immunology, s. 1960, 2023

• DOI för Author Correction: Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.

Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial

De Caterina, Raffaele; Patti, Giuseppe; Westerbergh, Johan; Horowitz, John et al.

Ingår i European Heart Journal - Cardiovascular Pharmacotherapy, s. 227-235, 2022

• DOI för Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial
• Ladda ner fulltext (pdf) av Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial

Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies

Gorski, Mathias; Rasheed, Humaira; Teumer, Alexander; Thomas, Laurent F. et al.

Ingår i Kidney International, s. 624-639, 2022

• DOI för Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies
• Ladda ner fulltext (pdf) av Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies

Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Aktaa, Suleman; Batra, Gorav; Cleland, John G. F.; Coats, Andrew et al.

Ingår i European Heart Journal, s. 2185-+, 2022

• DOI för Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)
• Ladda ner fulltext (pdf) av Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Serum Neurofilament Light Chain in Patients With Atrial Fibrillation

Sjölin, Karl; Aulin, Julia; Wallentin, Lars; Eriksson, Niclas et al.

Ingår i Journal of the American Heart Association, 2022

• DOI för Serum Neurofilament Light Chain in Patients With Atrial Fibrillation
• Ladda ner fulltext (pdf) av Serum Neurofilament Light Chain in Patients With Atrial Fibrillation

Genetic Landscape of the ACE2 Coronavirus Receptor

Yang, Zhijian; Macdonald-Dunlop, Erin; Chen, Jiantao; Zhai, Ranran et al.

Ingår i Circulation, s. 1398-1411, 2022

• DOI för Genetic Landscape of the ACE2 Coronavirus Receptor
• Ladda ner fulltext (pdf) av Genetic Landscape of the ACE2 Coronavirus Receptor

Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes

Batra, Gorav; Lindbäck, Johan; Becker, Richard C.; Harrington, Robert A. et al.

Ingår i Journal of the American College of Cardiology, s. 1735-1747, 2022

• DOI för Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes

Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Al-Khatib, Sana M.; Wojdyla, Daniel M.; Granger, Christopher B.; Wallentin, Lars et al.

Ingår i Circulation, s. 958-960, 2022

• DOI för Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Do we need to reconsider how we design and conduct randomized controlled trials?

Batra, Gorav; Wallentin, Lars

Ingår i European Heart Journal - Quality of Care and Clinical Outcomes, s. 374-376, 2022

• DOI för Do we need to reconsider how we design and conduct randomized controlled trials?
• Ladda ner fulltext (pdf) av Do we need to reconsider how we design and conduct randomized controlled trials?

Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events.

Siddiqui, Moneeza K; Smith, Gillian; St Jean, Pamela; Dawed, Adem Y et al.

Ingår i Diabetologia, s. 101-112, 2022

• DOI för Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events.
• Ladda ner fulltext (pdf) av Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events.

Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy.

Nelson, Thomas A; Parker, William A E; Ghukasyan, Tatevik; Westerbergh, Johan et al.

Ingår i Platelets, s. 425-431, 2022

• DOI för Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy.
• Ladda ner fulltext (pdf) av Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy.

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events

Attelind, Sofia; Hallberg, Pär; Wadelius, Mia; Hamberg, Anna-Karin et al.

Ingår i Frontiers in Genetics, 2022

• DOI för Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events
• Ladda ner fulltext (pdf) av Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Carnicelli, Anthony P.; Hong, Hwanhee; Connolly, Stuart J.; Eikelboom, John et al.

Ingår i Circulation, s. 242-255, 2022

• DOI för Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model

Aulin, Julia; Hijazi, Ziad; Lindbäck, Johan; Alexander, John H. et al.

Ingår i American Heart Journal, s. 13-24, 2022

• DOI för Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model
• Ladda ner fulltext (pdf) av Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model

Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials).

Attar, Rubina; Wu, Angie; Wojdyla, Daniel; Jensen, Svend Eggert et al.

Ingår i American Journal of Cardiology, s. 11-17, 2022

• DOI för Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials).

Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease - A STABILITY Substudy

Held, Claes; Hadziosmanovic, Nermin; Aylward, Philip E.; Hagström, Emil et al.

Ingår i Journal of the American Heart Association, 2022

• DOI för Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease - A STABILITY Substudy
• Ladda ner fulltext (pdf) av Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease - A STABILITY Substudy

Data standards for acute coronary syndrome and percutaneous coronary intervention: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart)

Batra, Gorav; Aktaa, Suleman; Wallentin, Lars; Maggioni, Aldo P. et al.

Ingår i European Heart Journal, s. 2269-2285, 2022

• DOI för Data standards for acute coronary syndrome and percutaneous coronary intervention: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart)
• Ladda ner fulltext (pdf) av Data standards for acute coronary syndrome and percutaneous coronary intervention: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart)

Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation

Hijazi, Ziad; Benz, Alexander P.; Lindbäck, Johan; Alexander, John H. et al.

Ingår i European Heart Journal, s. 208-218, 2022

• DOI för Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
• Ladda ner fulltext (pdf) av Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation

Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals

Winkler, Thomas W.; Rasheed, Humaira; Teumer, Alexander; Gorski, Mathias et al.

Ingår i Communications Biology, 2022

• DOI för Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals
• Ladda ner fulltext (pdf) av Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals

Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial

Batra, Gorav; Renlund, Henrik; Kunadian, Vijay; James, Stefan K. et al.

Ingår i European Heart Journal, s. 336-349, 2022

• DOI för Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial
• Ladda ner fulltext (pdf) av Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial

Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline

Gorski, Mathias; Jung, Bettina; Li, Yong; Matias-Garcia, Pamela R. et al.

Ingår i Kidney International, s. 926-939, 2021

• DOI för Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline
• Ladda ner fulltext (pdf) av Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline

Natriuretic peptides and incident atrial fibrillation

Tomasdottir, Maria; Held, Claes; Wallentin, Lars; Hijazi, Ziad

Ingår i American Heart Journal, s. 1-1, 2021

• DOI för Natriuretic peptides and incident atrial fibrillation

Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.

Pol, Tymon; Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas et al.

Ingår i Cardiovascular Research, s. 2112-2123, 2021

• DOI för Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.
• Ladda ner fulltext (pdf) av Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.

Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation.

Siegbahn, Agneta; Lindbäck, Johan; Hijazi, Ziad; Åberg, Mikael et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 2726-2737, 2021

• DOI för Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation.
• Ladda ner fulltext (pdf) av Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation.

Methodology for the development of international clinical data standards for common cardiovascular conditions: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart)

Batra, Gorav; Aktaa, Suleman; Wallentin, Lars; Maggioni, Aldo P et al.

Ingår i European Heart Journal - Quality of Care and Clinical Outcomes, s. 161-168, 2021

• DOI för Methodology for the development of international clinical data standards for common cardiovascular conditions: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart)
• Ladda ner fulltext (pdf) av Methodology for the development of international clinical data standards for common cardiovascular conditions: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart)

Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome

Batra, Gorav; Ghukasyan, Tatevik; Lindbäck, Johan; Held, Claes et al.

Ingår i JAMA cardiology, s. 1440-1445, 2021

• DOI för Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome

The SWEDEHEART secondary prevention and cardiac rehabilitation registry (SWEDEHEART CR registry)

Bäck, Maria; Leosdottir, Margret; Hagström, Emil; Norhammar, Anna et al.

Ingår i European Heart Journal - Quality of Care and Clinical Outcomes, s. 431-437, 2021

• DOI för The SWEDEHEART secondary prevention and cardiac rehabilitation registry (SWEDEHEART CR registry)

Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials

Mahmoodi, Bakhtawar K.; Eriksson, Niclas; Ross, Stephanie; Claassens, Daniel M. F. et al.

Ingår i Journal of the American Heart Association, 2021

• DOI för Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials
• Ladda ner fulltext (pdf) av Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials

Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome

Olszowka, Maciej; Held, Claes; Hadziosmanovic, Nermin; Denchev, Stefan et al.

Ingår i Journal of Internal Medicine, s. 392-403, 2021

• DOI för Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome
• Ladda ner fulltext (pdf) av Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome

Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale

Carnicelli, Anthony P; Hong, Hwanhee; Giugliano, Robert P; Connolly, Stuart J et al.

Ingår i American Heart Journal, s. 48-58, 2021

• DOI för Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale

Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study

Wallentin, Lars; Eriksson, Niclas; Olszowka, Maciej; Grammer, Tanja et al.

Ingår i PLoS Medicine, 2021

• DOI för Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study
• Ladda ner fulltext (pdf) av Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study

Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease

Benz, Alexander P.; Healey, Jeff S.; Chin, Ashley; Commerford, Patrick et al.

Ingår i Cardiovascular Research, s. 295-304, 2021

• DOI för Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease

Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality

Schunk, Stefan J.; Kleber, Marcus E.; März, Winfried; Pang, Shichao et al.

Ingår i European Heart Journal, s. 1742-1756, 2021

• DOI för Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality

Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis

Mahmoodi, Bakhtawar K.; Eriksson, Niclas; Vos, Gerrit J. A.; Meijer, Karina et al.

Ingår i Journal of the American Heart Association, 2021

• DOI för Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis
• Ladda ner fulltext (pdf) av Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis

Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation

Carnicelli, Anthony P.; Al-Khatib, Sana M.; Xavier, Denis; Dalgaard, Frederik et al.

Ingår i Heart, s. 713-720, 2021

• DOI för Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation

Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation

Benz, Alexander P.; Hijazi, Ziad; Lindbäck, Johan; Connolly, Stuart J. et al.

Ingår i Circulation, s. 1863-1873, 2021

• DOI för Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation

Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas

Pol, Tymon; Hijazi, Ziad; Lindbäck, Johan; Alexander, John H. et al.

Ingår i Open heart, 2021

• DOI för Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas
• Ladda ner fulltext (pdf) av Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas

Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial)

Millenaar, Dominic; Schumacher, Helmut; Brueckmann, Martina; Eikelboom, John W. et al.

Ingår i American Journal of Cardiology, s. 27-35, 2021

• DOI för Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial)

Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial

Al-Khatib, Sana M.; Mulder, Hillary; Wojdyla, Daniel; Lopes, Renato D. et al.

Ingår i Circulation, s. 359-361, 2021

• DOI för Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial

Risk markers of incident atrial fibrillation in patients with coronary heart disease

Tomasdottir, Maria; Held, Claes; Hadziosmanovic, Nermin; Westerbergh, Johan et al.

Ingår i American Heart Journal, s. 92-101, 2021

• DOI för Risk markers of incident atrial fibrillation in patients with coronary heart disease
• Ladda ner fulltext (pdf) av Risk markers of incident atrial fibrillation in patients with coronary heart disease

Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19

Klaric, Lucija; Gisby, Jack S; Papadaki, Artemis; Muckian, Marisa D et al.

Ingår i medRxiv : the preprint server for health sciences, s. 1-28, 2021

• DOI för Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19

Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Gregersen, Ida; Michelsen, Annika E.; Lunde, Ngoc Nguyen; Åkerblom, Axel et al.

Ingår i Journal of the American Heart Association, 2020

• DOI för Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis

Kloosterman, Marielle; Oldgren, Jonas; Conen, David; Wong, Jorge A. et al.

Ingår i Europace, s. 870-877, 2020

• DOI för Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis

Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation

Hijazi, Ziad; Wallentin, Lars; Lindbäck, Johan; Alexander, John H. et al.

Ingår i Journal of the American Heart Association, 2020

• DOI för Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation
• Ladda ner fulltext (pdf) av Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation

Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals

Folkersen, Lasse; Gustafsson, Stefan; Wang, Qin; Hvidberg Hansen, Daniel et al.

Ingår i Nature Metabolism, s. 1135-1148, 2020

• DOI för Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals

Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.

Aulin, Julia; Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 2287-2295, 2020

• DOI för Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.
• Ladda ner fulltext (pdf) av Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.

Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.

Wallentin, Lars; Lindbäck, Johan; Eriksson, Niclas; Hijazi, Ziad et al.

Ingår i European Heart Journal, s. 4037-4046, 2020

• DOI för Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.

Association of Factor V Leiden With Subsequent Atherothrombotic Events A GENIUS-CHD Study of Individual Participant Data

Mahmoodi, Bakhtawar K.; Tragante, Vinicius; Kleber, Marcus E.; Holmes, Michael V. et al.

Ingår i Circulation, s. 546-555, 2020

• DOI för Association of Factor V Leiden With Subsequent Atherothrombotic Events A GENIUS-CHD Study of Individual Participant Data

Extracellular vesicles in atrial fibrillation and stroke

Thulin, Åsa; Lindbäck, Johan; Granger, Christopher B.; Wallentin, Lars et al.

Ingår i Thrombosis Research, s. 180-189, 2020

• DOI för Extracellular vesicles in atrial fibrillation and stroke
• Ladda ner fulltext (pdf) av Extracellular vesicles in atrial fibrillation and stroke

Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial

Garcia, David A; Fisher, Deborah A; Mulder, Hillary; Wruck, Lisa et al.

Ingår i American Heart Journal, s. 1-8, 2020

• DOI för Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial

Understanding the use of observational and randomized data in cardiovascular medicine

Bowman, Louise; Baras, Aris; Bombien, Rene; Califf, Robert M. et al.

Ingår i European Heart Journal, s. 2571-2578, 2020

• DOI för Understanding the use of observational and randomized data in cardiovascular medicine

ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial

Ueland, Thor; Åkerblom, Axel; Ghukasyan, Tatevik; Michelsen, Annika E et al.

Ingår i Atherosclerosis, s. 35-41, 2020

• DOI för ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial

Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy

Hilvo, Mika; Wallentin, Lars; Ghukasyan, Tatevik; Held, Claes et al.

Ingår i Journal of the American Heart Association, 2020

• DOI för Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy
• Ladda ner fulltext (pdf) av Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy

Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease

Stanifer, John W.; Pokorney, Sean D.; Chertow, Glenn M.; Hohnloser, Stefan H. et al.

Ingår i Circulation, s. 1384-1392, 2020

• DOI för Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease

Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V.

Ferrannini, Giulia; De Bacquer, Dirk; De Backer, Guy; Kotseva, Kornelia et al.

Ingår i Diabetes Care, s. 726-733, 2020

• DOI för Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V.

No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials.

Sabatine, Marc S; Hiatt, William R; Goto, Shinya; Johnston, S Claiborne et al.

Ingår i JACC, s. 1012-1014, 2020

• DOI för No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials.

Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study

McAlister, Finlay A.; Mian, Rajibul; Oldgren, Jonas; Wallentin, Lars et al.

Ingår i PLOS ONE, 2020

• DOI för Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study
• Ladda ner fulltext (pdf) av Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study

Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial

Kontny, Frederic; Andersen, Thomas; Ueland, Thor; Åkerblom, Axel et al.

Ingår i European Heart Journal, s. 313-322, 2020

• DOI för Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial

Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation

Hijazi, Ziad; Granger, Christopher B.; Hohnloser, Stefan H.; Westerbergh, Johan et al.

Ingår i Journal of the American Heart Association, 2020

• DOI för Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation

Effects of apixaban compared with warfarin as gain in event-free time: a novel assessment of the results of the ARISTOTLE trial

Berglund, Erik; Wallentin, Lars; Oldgren, Jonas; Renlund, Henrik et al.

Ingår i European Journal of Preventive Cardiology, s. 1311-1319, 2020

• DOI för Effects of apixaban compared with warfarin as gain in event-free time: a novel assessment of the results of the ARISTOTLE trial
• Ladda ner fulltext (pdf) av Effects of apixaban compared with warfarin as gain in event-free time: a novel assessment of the results of the ARISTOTLE trial

Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial

Zeitouni, Michel; Giczewska, Anna; Lopes, Renato D.; Wojdyla, Daniel M. et al.

Ingår i Journal of the American College of Cardiology, s. 1145-1155, 2020

• DOI för Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial

Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Ingår i JAMA Network Open, 2020

• DOI för Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials

In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events

White, Harvey D.; Stewart, Ralph A. H.; Dolby, Anthony J.; Stebbins, Amanda et al.

Ingår i American Heart Journal, s. 97-107, 2020

• DOI för In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events

Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI

Marquis-Gravel, Guillaume; Dalgaard, Frederik; Jones, Aaron D.; Lokhnygina, Yuliya et al.

Ingår i Journal of the American College of Cardiology, s. 162-171, 2020

• DOI för Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI

Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDEHEART registry

Simonsson, Moa; Wallentin, Lars; Alfredsson, Joakim; Erlinge, David et al.

Ingår i European Heart Journal, s. 833-843, 2020

• DOI för Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDEHEART registry

Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics.

Morales-Rosado, Joel A; Goel, Kashish; Zhang, Lingxin; Åkerblom, Axel et al.

Ingår i Cardiovascular Drugs and Therapy, s. 549-559, 2020

• DOI för Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics.

Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial

Rosjo, H.; Hijazi, Ziad; Omland, T.; Westerbergh, Johan et al.

Ingår i Journal of Internal Medicine, s. 248-259, 2020

• DOI för Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial
• Ladda ner fulltext (pdf) av Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial

Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial

Dalgaard, Frederik; Mulder, Hillary; Wojdyla, Daniel M.; Lopes, Renato D. et al.

Ingår i Circulation, s. 10-20, 2020

• DOI för Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial

Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial

Bahit, M. Cecilia; Granger, Christopher B.; Alexander, John H.; Mulder, Hillary et al.

Ingår i International Journal of Cardiology, s. 53-58, 2020

• DOI för Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial

Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial

Böhm, Michael; Brueckmann, Martina; Eikelboom, John W.; Ezekowitz, Michael et al.

Ingår i European Heart Journal, s. 2848-2859, 2020

• DOI för Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial

Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study

Sumaya, Wael; Wallentin, Lars; James, Stefan; Siegbahn, Agneta et al.

Ingår i Thrombosis and Haemostasis, s. 412-422, 2020

• DOI för Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study
• Ladda ner fulltext (pdf) av Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study

Comparative Efficacy and Safety of Oral P2Y₁₂ Inhibitors in Acute Coronary Syndrome Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials

Navarese, Eliano P.; Khan, Safi U.; Kolodziejczak, Michalina; Kubica, Jacek et al.

Ingår i Circulation, s. 150-160, 2020

• DOI för Comparative Efficacy and Safety of Oral P2Y₁₂ Inhibitors in Acute Coronary Syndrome Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials

Cardiovascular Medicine in Sweden Improvement by Continuous Measuring

Rosengren, Annika; Wallentin, Lars

Ingår i Circulation, s. 1124-1126, 2020

• DOI för Cardiovascular Medicine in Sweden Improvement by Continuous Measuring

Ticagrelor in patients with heart failure after acute coronary syndromes - Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

Åkerblom, Axel; Wojdyla, Daniel M.; Wallentin, Lars; James, Stefan et al.

Ingår i American Heart Journal, s. 57-65, 2019

• DOI för Ticagrelor in patients with heart failure after acute coronary syndromes - Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention

Kessler, Thorsten; Wolf, Bernhard; Eriksson, Niclas; Kofink, Daniel et al.

Ingår i Cardiovascular Research, s. 1512-1518, 2019

• DOI för Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention

Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial

Alexander, Karen P; Brouwer, Marc A; Mulder, Hillary; Vinereanu, Dragos et al.

Ingår i American Heart Journal, s. 123-131, 2019

• DOI för Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial

Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial

Washam, Jeffrey B.; Hohnloser, Stefan H.; Lopes, Renato D.; Wojdyla, Daniel M. et al.

Ingår i Journal of Thrombosis and Thrombolysis, s. 345-352, 2019

• DOI för Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial

Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution

Justice, Anne E.; Giedraitis, Vilmantas; Gustafsson, Stefan; Ingelsson, Erik et al.

Ingår i Nature Genetics, s. 452-469, 2019

• DOI för Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution

Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials

Nunez, Derek J; Alexander, Myriam; Yerges-Armstrong, Laura; Singh, Gurparkash et al.

Ingår i American Journal of Physiology - Gastrointestinal and Liver Physiology, 2019

• DOI för Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials

Natriuretic peptide should be used as a routine tool for evaluation of patients with atrial fibrillation

Hijazi, Ziad; Wallentin, Lars

Ingår i Heart, s. 353-354, 2019

• DOI för Natriuretic peptide should be used as a routine tool for evaluation of patients with atrial fibrillation

Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes

Ueland, Thor; Åkerblom, Axel; Ghukasyan, Tatevik; Michelsen, Annika E et al.

Ingår i Arteriosclerosis, Thrombosis and Vascular Biology, s. 294-302, 2019

• DOI för Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes

Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study

Parker, William A E; Eriksson, Niclas; Becker, Richard C; Voora, Deepak et al.

Ingår i Platelets, s. 579-588, 2019

• DOI för Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study

Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel.

Thomas, Mark R.; James, Stefan; Becker, Richard C.; Himmelmann, Anders et al.

Ingår i European Heart Journal, s. 153-163, 2019

• DOI för Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel.

Editor's Choice- Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction

Erlinge, David; Koul, Sasha; Omerovic, Elmir; Frobert, Ole et al.

Ingår i European Heart Journal, s. 492-501, 2019

• DOI för Editor's Choice- Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials

Fanaroff, Alexander C.; Clare, Robert; Pieper, Karen S.; Mahaffey, Kenneth W. et al.

Ingår i Circulation, s. 863-873, 2019

• DOI för Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials

Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight: Insights From the ARISTOTLE Trial

Hohnloser, Stefan H.; Fudim, Marat; Alexander, John H.; Wojdyla, Daniel M. et al.

Ingår i Circulation, s. 2292-2300, 2019

• DOI för Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight: Insights From the ARISTOTLE Trial

Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial

Sharma, Abhinav; Hagström, Emil; Wojdyla, Daniel M.; Neely, Megan L. et al.

Ingår i American Heart Journal, s. 106-113, 2019

• DOI för Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial

Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial

Hijazi, Ziad; Verdecchia, Paolo; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Journal of the American Heart Association, 2019

• DOI för Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial
• Ladda ner fulltext (pdf) av Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial

Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial

Guimaraes, Patricia O.; Pokorney, Sean D.; Lopes, Renato D.; Wojdyla, Daniel M. et al.

Ingår i Clinical Cardiology, s. 568-571, 2019

• DOI för Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial
• Ladda ner fulltext (pdf) av Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial

Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease

Stewart, Ralph A. H.; Held, Claes; Krug-Gourley, Sue; Waterworth, Dawn et al.

Ingår i Journal of the American Heart Association, 2019

• DOI för Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease
• Ladda ner fulltext (pdf) av Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease

Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y₁₂ Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial

Franchi, Francesco; James, Stefan; Ghukasyan, Tatevik; Budaj, Andrzej J. et al.

Ingår i Journal of the American Heart Association, 2019

• DOI för Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y₁₂ Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial
• Ladda ner fulltext (pdf) av Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y₁₂ Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial

Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome

Ernst, Diana; Westerbergh, Johan; Sogkas, Georgios; Jablonka, Alexandra et al.

Ingår i Scientific Reports, 2019

• DOI för Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome
• Ladda ner fulltext (pdf) av Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome

Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

Åkerblom, Axel; Wojdyla, Daniel; Steg, Philippe Gabriel; Wallentin, Lars et al.

Ingår i Journal of Thrombosis and Thrombolysis, s. 563-569, 2019

• DOI för Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
• Ladda ner fulltext (pdf) av Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial

Held, Claes; White, Harvey D.; Stewart, Ralph A. H.; Davies, Richard et al.

Ingår i American Heart Journal, s. 65-73, 2019

• DOI för Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial
• Ladda ner fulltext (pdf) av Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.

Christersson, Christina; Wallentin, Lars; Andersson, Ulrika; Alexander, John H et al.

Ingår i Heart, s. 235-242, 2019

• DOI för Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.
• Ladda ner fulltext (pdf) av Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.

C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes

Andersen, Thomas; Ueland, Thor; Ghukasyan Lakic, Tatevik; Åkerblom, Axel et al.

Ingår i Arteriosclerosis, Thrombosis and Vascular Biology, s. 2402-2410, 2019

• DOI för C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes

Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial)

Goldstein, Sarah A.; Green, Jennifer; Huber, Kurt; Wojdyla, Daniel M. et al.

Ingår i American Journal of Cardiology, s. 1406-1412, 2019

• DOI för Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial)

Subsequent Event Risk in Individuals With Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium

Patel, Riyaz S.; Tragante, Vinicius; Schmidt, Amand F.; McCubrey, Raymond O. et al.

Ingår i Circulation, 2019

• DOI för Subsequent Event Risk in Individuals With Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium
• Ladda ner fulltext (pdf) av Subsequent Event Risk in Individuals With Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium

Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data

Patel, Riyaz S.; Schmidt, Amand F.; Tragante, Vinicius; McCubrey, Raymond O. et al.

Ingår i Circulation, 2019

• DOI för Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data
• Ladda ner fulltext (pdf) av Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data

A catalog of genetic loci associated with kidney function from analyses of a million individuals

Wuttke, Matthias; Li, Yong; Li, Man; Sieber, Karsten B. et al.

Ingår i Nature Genetics, s. 957-972, 2019

• DOI för A catalog of genetic loci associated with kidney function from analyses of a million individuals

EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials

Wallentin, Lars; Gale, Chris P.; Maggioni, Aldo; Bardinet, Isabel et al.

Ingår i European Heart Journal, s. 2745-2749, 2019

• DOI för EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials

Uppsala Clinical Research Center: development of a platform to promote national and international clinical science

Wallentin, Lars; Lindahl, Bertil

Ingår i Upsala Journal of Medical Sciences, s. 1-5, 2019

• DOI för Uppsala Clinical Research Center: development of a platform to promote national and international clinical science
• Ladda ner fulltext (pdf) av Uppsala Clinical Research Center: development of a platform to promote national and international clinical science

Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial

Sandhu, Roopinder K.; Ezekowitz, Justin A.; Hijazi, Ziad; Westerbergh, Johan et al.

Ingår i Open heart, 2018

• DOI för Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial
• Ladda ner fulltext (pdf) av Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial

Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation

Kent, Anthony P.; Brueckmann, Martina; Fraessdorf, Mandy; Connolly, Stuart J. et al.

Ingår i Journal of the American College of Cardiology, s. 255-267, 2018

• DOI för Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation

Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease

Vinereanu, Dragos; Wang, Alice; Mulder, Hillary; Lopes, Renato D. et al.

Ingår i Heart, s. 1292-1299, 2018

• DOI för Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease

Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis

Scirica, Benjamin M.; Bansilal, Sameer; Davoudi, Farideh; Armstrong, Paul W. et al.

Ingår i American Heart Journal, s. 54-60, 2018

• DOI för Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis

Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial

Tricoci, Pierluigi; Neely, Megan; Whitley, Michael J.; Edelstein, Leonard C. et al.

Ingår i Blood Cells, Molecules & Diseases, s. 37-43, 2018

• DOI för Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial

Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy

Horowitz, John D.; De Caterina, Raffaele; Heresztyn, Tamila; Alexander, John H. et al.

Ingår i Journal of the American College of Cardiology, s. 721-733, 2018

• DOI för Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy

Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran

Kolb, Jennifer M.; Flack, Kathryn Friedman; Chatterjee-Murphy, Prapti; Desai, Jay et al.

Ingår i Digestive Diseases and Sciences, s. 1878-1889, 2018

• DOI för Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran

Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014

Szummer, Karolina; Wallentin, Lars C.; Lindhagen, Lars; Alfredsson, Joakim et al.

Ingår i European Heart Journal, s. 3766-3776, 2018

• DOI för Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014

Så blev NOAK den dominerande behandlingen vid förmaksflimmer: Historiskt perspektiv på den kliniska utvecklingen

Wallentin, Lars

Ingår i Läkartidningen, 2018

Lp-PLA(2), scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease

Manichaikul, Ani; Wang, Xin-Qun; Li, Li; Erdmann, Jeanette et al.

Ingår i PLOS ONE, 2018

• DOI för Lp-PLA(2), scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease
• Ladda ner fulltext (pdf) av Lp-PLA(2), scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease

Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study

Lindholm, Daniel P; James, Stefan K; Gabrysch, Katja; Storey, Robert F et al.

Ingår i JAMA cardiology, s. 1160-1166, 2018

• DOI för Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study

Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome

Inohara, Taku; Pieper, Karen; Wojdyla, Daniel M.; Patel, Manesh R. et al.

Ingår i American Heart Journal, s. 25-32, 2018

• DOI för Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Ingår i European Heart Journal, s. 477-485, 2018

• DOI för A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score
• Ladda ner fulltext (pdf) av A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score

Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation-the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study

Verdecchia, Paolo; Reboldi, Gianpaolo; Angeli, Fabio; Mazzotta, Giovanni et al.

Ingår i Europace, s. 253-262, 2018

• DOI för Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation-the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study
• Ladda ner fulltext (pdf) av Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation-the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study

Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

Guimarães, Patrícia O; Leonardi, Sergio; Huang, Zhen; Wallentin, Lars et al.

Ingår i American Heart Journal, s. 28-35, 2018

• DOI för Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease

Hagström, Emil; Norlund, Fredrika; Stebbins, Amanda; Armstrong, P W et al.

Ingår i Journal of Internal Medicine, s. 83-92, 2018

• DOI för Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease

Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Sharma, Abhinav; Hijazi, Ziad; Andersson, Ulrika; Al-Khatib, Sana M. et al.

Ingår i Circulation, s. 1666-1676, 2018

• DOI för Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis

Rocca, Bianca; Fox, Keith A. A.; Ajjan, Ramzi A.; Andreotti, Felicita et al.

Ingår i European Heart Journal, s. 1672-1686, 2018

• DOI för Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis

Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial

Rao, Meena P; Vinereanu, Dragos; Wojdyla, Daniel M; Alexander, John H et al.

Ingår i American Journal of Medicine, s. 269-27500, 2018

• DOI för Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial

Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy

Sumaya, Wael; Wallentin, Lars; James, Stefan K.; Siegbahn, Agneta et al.

Ingår i European Heart Journal, s. 1078-1085, 2018

• DOI för Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy
• Ladda ner fulltext (pdf) av Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy

New Biomarkers Associated With Cardiovascular Death In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Pol, Tymon; Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas et al.

Ingår i Journal of the American College of Cardiology, s. 330-330, 2018

• DOI för New Biomarkers Associated With Cardiovascular Death In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Novel Prognostic Biomarkers For Ischemic Stroke In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Hijazi, Ziad; Pol, Tymon; Oldgren, Jonas; Lindbäck, Johan et al.

Ingår i Journal of the American College of Cardiology, s. 506-506, 2018

Novel Cyp2C19 Genetic Variants associated with Stent Thrombosis: a Next Generation Sequencing Study

Goel, Kashish; Baheti, Saurabh; Åkerblom, Axel; Eriksson, Niclas et al.

Ingår i Journal of the American College of Cardiology, s. 1205-1205, 2018

• DOI för Novel Cyp2C19 Genetic Variants associated with Stent Thrombosis: a Next Generation Sequencing Study

Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i American Heart Journal, s. 169-177, 2018

• DOI för Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE

Goto, Shinya; Merrill, Peter; Wallentin, Lars; Wojdyla, Daniel M. et al.

Ingår i European Heart Journal - Cardiovascular Pharmacotherapy, s. 75-81, 2018

• DOI för Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE

Digoxin and Mortality in Patients With Atrial Fibrillation

Lopes, Renato D.; Rordorf, Roberto; De Ferrari, Gaetano M.; Leonardi, Sergio et al.

Ingår i Journal of the American College of Cardiology, s. 1063-1074, 2018

• DOI för Digoxin and Mortality in Patients With Atrial Fibrillation

Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Ueland, Thor; Åkerblom, Axel; Ghukasyan, Tatevik; Michelsen, Annika E. et al.

Ingår i Journal of the American Heart Association, 2018

• DOI för Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial
• Ladda ner fulltext (pdf) av Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial

Ungar, Leo; Clare, Robert M.; Rodriguez, Fatima; Kolls, Bradley J. et al.

Ingår i Journal of the American Heart Association, 2018

• DOI för Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
• Ladda ner fulltext (pdf) av Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial

Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial

Sherwood, Matthew W; Lopes, Renato D; Sun, Jie Lena; Liaw, Danny et al.

Ingår i American Heart Journal, s. 1-8, 2018

• DOI för Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial

Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial

Kopin, David; Jones, W Schuyler; Sherwood, Matthew W; Wojdyla, Daniel M et al.

Ingår i American Heart Journal, s. 133-141, 2018

• DOI för Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial

Different perspectives on outcomes in patients with non-ST-elevation myocardial infarction when observed in clinical trials and in real life

Wallentin, Lars

Ingår i European Heart Journal, s. 3821-3824, 2018

• DOI för Different perspectives on outcomes in patients with non-ST-elevation myocardial infarction when observed in clinical trials and in real life
• Ladda ner fulltext (pdf) av Different perspectives on outcomes in patients with non-ST-elevation myocardial infarction when observed in clinical trials and in real life

Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

Turcot, Valerie; Lu, Yingchang; Highland, Heather M.; Schurmann, Claudia et al.

Ingår i Nature Genetics, s. 26-+, 2018

• DOI för Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study

Storey, Robert F.; Ardissino, Diego; Vignali, Luigi; Cairns, Richard et al.

Ingår i Thrombosis and Haemostasis, s. 427-429, 2018

• DOI för Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study

Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention

Batra, Gorav; Friberg, Leif; Erlinge, David; James, Stefan K et al.

Ingår i European Heart Journal - Cardiovascular Pharmacotherapy, s. 36-45, 2018

• DOI för Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention

Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial

Proietti, M.; Hijazi, Ziad; Andersson, Ulrika; Connolly, S. J. et al.

Ingår i Journal of Internal Medicine, s. 282-292, 2018

• DOI för Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial

Potent P2Y(12) Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials

Lau, Emily S.; Braunwald, Eugene; Murphy, Sabina A.; Wiviott, Stephen D. et al.

Ingår i Journal of the American College of Cardiology, s. 1549-1559, 2017

• DOI för Potent P2Y(12) Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials

Platelet-related biomarkers and their response to inhibition with aspirin and p2y₁₂-receptor antagonists in patients with acute coronary syndrome

Lowenstern, Angela; Storey, Robert F.; Neely, Megan; Sun, Jie-Lena et al.

Ingår i Journal of Thrombosis and Thrombolysis, s. 145-153, 2017

• DOI för Platelet-related biomarkers and their response to inhibition with aspirin and p2y₁₂-receptor antagonists in patients with acute coronary syndrome

Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

Hijazi, Ziad; Lindahl, Bertil; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Journal of the American Heart Association, 2017

• DOI för Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome

Hess, Connie N.; Clare, Robert M.; Neely, Megan L.; Tricoci, Pierluigi et al.

Ingår i American Heart Journal, s. 194-203, 2017

• DOI för Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome

An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome

Pagidipati, Neha J.; Hess, Connie N.; Clare, Robert M.; Akerblom, Axel et al.

Ingår i American Heart Journal, s. 53-61, 2017

• DOI för An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome

Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes

Ducrocq, Gregory; Schulte, Phillip J.; Budaj, Andrzej; Cornel, Jan H. et al.

Ingår i American Heart Journal, s. 91-99, 2017

• DOI för Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes

Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor

Gaglia, Michael A.; Lipinski, Michael J.; Lhermusier, Thibault; Steinvil, Arie et al.

Ingår i American Journal of Cardiology, s. 1135-1140, 2017

• DOI för Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor

Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial

Guimaraes, Patricia O.; Wojdyla, Daniel M.; Alexander, John H.; Thomas, Laine et al.

Ingår i International Journal of Cardiology, s. 443-449, 2017

• DOI för Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial

Hu, Peter T.; Lopes, Renato D.; Stevens, Susanna R.; Wallentin, Lars et al.

Ingår i Journal of the American Heart Association, 2017

• DOI för Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial

Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial

Pollack, Charles V.; Davoudi, Farideh; Diercks, Deborah B.; Becker, Richard C. et al.

Ingår i Clinical Cardiology, s. 390-398, 2017

• DOI för Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial

Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease

Lindholm, Daniel; Lindbäck, Johan; Armstrong, Paul W.; Budaj, Andrzej et al.

Ingår i Journal of the American College of Cardiology, s. 813-826, 2017

• DOI för Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease

Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognosticmodels for cardiovascular events and bleeding in myocardial infarction survivors

Pasea, Laura; Chung, Sheng-Chia; Pujades-Rodriguez, Mar; Moayyeri, Alireza et al.

Ingår i European Heart Journal, s. 1048-1055A, 2017

• DOI för Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognosticmodels for cardiovascular events and bleeding in myocardial infarction survivors
• Ladda ner fulltext (pdf) av Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognosticmodels for cardiovascular events and bleeding in myocardial infarction survivors

Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial

Westenbrink, B. Daan; Alings, Marco; Granger, Christopher B.; Alexander, John H. et al.

Ingår i American Heart Journal, s. 140-149, 2017

• DOI för Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
• Ladda ner fulltext (pdf) av Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation

Bahit, M. Cecilia; Lopes, Renato D.; Wojdyla, Daniel M.; Held, Claes et al.

Ingår i Heart, s. 623-628, 2017

• DOI för Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
• Ladda ner fulltext (pdf) av Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation

Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease

Hagström, Emil; Held, Claes; Stewart, Ralph A H; Aylward, Philip E et al.

Ingår i Clinical Chemistry, s. 325-333, 2017

• DOI för Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease

Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy.

Giannitsis, Evangelos; Wallentin, Lars; James, Stefan K; Bertilsson, Maria et al.

Ingår i European Heart Journal, s. 500-510, 2017

• DOI för Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy.

Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial

Valgimigli, Marco; Costa, Francesco; Lokhnygina, Yuliya; Clare, Robert M. et al.

Ingår i European Heart Journal, s. 804-810, 2017

• DOI för Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial

Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.

Lindholm, Daniel P; Hagström, Emil; James, Stefan K; Becker, Richard C et al.

Ingår i Journal of the American Heart Association, 2017

• DOI för Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
• Ladda ner fulltext (pdf) av Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.

Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial

Cowper, Patricia A.; Sheng, Shubin; Lopes, Renato D.; Anstrom, Kevin J. et al.

Ingår i JAMA cardiology, s. 525-534, 2017

• DOI för Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J et al.

Ingår i American Heart Journal, s. 94-103, 2017

• DOI för Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial

Harskamp, Ralf E.; Clare, Robert M.; Ambrosio, Giuseppe; Held, Claes et al.

Ingår i European Heart Journal, s. 155-163, 2017

• DOI för Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial

Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease

Vedin, Ola; Hagström, Emil; Östlund, Ollie; Avezum, Alvaro et al.

Ingår i International Journal of Cardiology, s. 271-276, 2017

• DOI för Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease

Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk

Braenne, Ingrid; Zeng, Lingyao; Willenborg, Christina; Tragante, Vinicius et al.

Ingår i PLOS ONE, 2017

• DOI för Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk

Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease

Stewart, Ralph A H; Hagström, Emil; Held, Claes; Wang, Tom Kai Ming et al.

Ingår i Journal of the American Heart Association, 2017

• DOI för Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease
• Ladda ner fulltext (pdf) av Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease

Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin

Vinereanu, Dragos; Lopes, Renato D; Mulder, Hillary; Gersh, Bernard J et al.

Ingår i Stroke, s. 3266-3273, 2017

• DOI för Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin

Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial

Bellavia, Andrea; Wallentin, Lars; Orsini, Nicola; James, Stefan K et al.

Ingår i Open heart, 2017

• DOI för Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial
• Ladda ner fulltext (pdf) av Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial

Antibodies against MYC-Associated Zinc Finger Protein: An Independent Marker in Acute Coronary Syndrome?

Ernst, Diana; Widera, Christian; Baerlecken, Niklas T; Schlumberger, Wolfgang et al.

Ingår i Frontiers in Immunology, 2017

• DOI för Antibodies against MYC-Associated Zinc Finger Protein: An Independent Marker in Acute Coronary Syndrome?
• Ladda ner fulltext (pdf) av Antibodies against MYC-Associated Zinc Finger Protein: An Independent Marker in Acute Coronary Syndrome?

Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect

Guimarães, Patrícia O; Lopes, Renato D; Wojdyla, Daniel M; Abdul-Rahim, Azmil H et al.

Ingår i Cardiovascular Drugs and Therapy, s. 295-301, 2017

• DOI för Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect

Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014

Szummer, Karolina; Wallentin, Lars; Lindhagen, Lars; Alfredsson, Joakim et al.

Ingår i European Heart Journal, s. 3056-3065, 2017

• DOI för Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014
• Ladda ner fulltext (pdf) av Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014

Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial

Held, Claes; White, Harvey D.; Stewart, Ralph A. H.; Budaj, Andrzej et al.

Ingår i Journal of the American Heart Association, 2017

• DOI för Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial

Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial

Vidal-Petiot, Emmanuelle; Stebbins, Amanda; Chiswell, Karen; Ardissino, Diego et al.

Ingår i European Heart Journal, s. 2813-2822, 2017

• DOI för Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial

Bivalirudin versus Heparin Monotherapy in Myocardial Infarction

Erlinge, D.; Omerovic, E.; Fröbert, O.; Linder, R. et al.

Ingår i New England Journal of Medicine, s. 1132-1142, 2017

• DOI för Bivalirudin versus Heparin Monotherapy in Myocardial Infarction

Physical Activity and Mortality in Patients With Stable Coronary Heart Disease

Stewart, Ralph A. H.; Held, Claes; Hadziosmanovic, Nermin; Armstrong, Paul W. et al.

Ingår i Journal of the American College of Cardiology, s. 1689-1700, 2017

• DOI för Physical Activity and Mortality in Patients With Stable Coronary Heart Disease

Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial

Guimaraes, Patricia Oliveira; Granger, Christopher B.; Stebbins, Amanda; Chiswell, Karen et al.

Ingår i Journal of the American Heart Association, 2017

• DOI för Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
• Ladda ner fulltext (pdf) av Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial

A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors

Brænne, Ingrid; Willenborg, Christina; Tragante, Vinicius; Kessler, Thorsten et al.

Ingår i Scientific Reports, 2017

• DOI för A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors
• Ladda ner fulltext (pdf) av A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors

Women with stable coronary artery disease have better clinical outcomes than men, but this association is modified by degree of depression: insights from the STABILITY trial

Guimaraes, P. Oliveira; Granger, C. B.; Chiswell, K.; Stebbins, A. et al.

Ingår i European Heart Journal, s. 188-188, 2017

• DOI för Women with stable coronary artery disease have better clinical outcomes than men, but this association is modified by degree of depression: insights from the STABILITY trial

Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome

Lindholm, Daniel P; James, Stefan K; Bertilsson, Maria; Becker, Richard C et al.

Ingår i Clinical Chemistry, s. 573-584, 2017

• DOI för Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study

Zewinger, Stephen; Kleber, Marcus E.; Tragante, Vinicius; McCubrey, Raymond O. et al.

Ingår i The Lancet Diabetes and Endocrinology, s. 534-543, 2017

• DOI för Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study

Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib

Yeo, Astrid; Li, Li; Warren, Liling; Aponte, Jennifer et al.

Ingår i PLOS ONE, 2017

• DOI för Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib
• Ladda ner fulltext (pdf) av Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib

Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial.

Melloni, Chiara; Dunning, Allison; Granger, Christopher B; Thomas, Laine et al.

Ingår i American Journal of Medicine, s. 1440-14480, 2017

• DOI för Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial.

Unreliable Observations from a Confounded Analysis of a Skewed Database

Steg, Philippe Gabriel; Harrington, Robert A.; Himmelmann, Anders; James, Stefan K et al.

Ingår i American Journal of Medicine, 2017

• DOI för Unreliable Observations from a Confounded Analysis of a Skewed Database

Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials

Costa, Francesco; van Klaveren, David; James, Stefan K; Heg, Dik et al.

Ingår i The Lancet, s. 1025-1034, 2017

• DOI för Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials

Effects of dabigatran according to age in atrial fibrillation

Lauw, Mandy N.; Eikelboom, John W.; Coppens, Michiel; Wallentin, Lars et al.

Ingår i Heart, s. 1015-1023, 2017

• DOI för Effects of dabigatran according to age in atrial fibrillation

Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy

Lopes, Renato D.; Guimaraes, Patricia O.; Kolls, Bradley J.; Wojdyla, Daniel M. et al.

Ingår i Blood, s. 2980-2987, 2017

• DOI för Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy

Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation

Flack, Kathryn F.; Desai, Jay; Kolb, Jennifer M.; Chatterjee, Prapti et al.

Ingår i Clinical Gastroenterology and Hepatology, s. 682-690, 2017

• DOI för Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation

Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial

Alexander, John H; Andersson, Ulrika; Lopes, Renato D; Hijazi, Ziad et al.

Ingår i JAMA cardiology, s. 673-681, 2016

• DOI för Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial

The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial

Sandhu, Roopinder K.; Ezekowitz, Justin; Andersson, Ulrika; Alexander, John H. et al.

Ingår i European Heart Journal, s. 2869-2878, 2016

• DOI för The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial

Hijazi, Ziad; Hohnloser, Stefan H; Andersson, Ulrika; Alexander, John H et al.

Ingår i JAMA cardiology, s. 451-460, 2016

• DOI för Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial

Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation

Oldgren, Jonas; Hijazi, Ziad; Lindbäck, Johan; Alexander, John H et al.

Ingår i Circulation, s. 1697-1707, 2016

• DOI för Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)

Ezekowitz, Michael D.; Nagarakanti, Rangadham; Noack, Herbert; Brueckmann, Martina et al.

Ingår i Circulation, s. 589-598, 2016

• DOI för Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)

Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: experiences from the RELY trial

Hijazi, Ziad; Verdecchia, P.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i EUROPEAN HEART JOURNAL, s. 47-47, 2016

Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART)

Sahlen, Anders; Varenhorst, Christoph; Lagerqvist, Bo; Renlund, Henrik et al.

Ingår i EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, s. 5-12, 2016

• DOI för Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART)
• Ladda ner fulltext (pdf) av Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART)

Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation

Ezekowitz, Michael D.; Eikelboom, John; Oldgren, Jonas; Reilly, Paul A. et al.

Ingår i Europace, s. 973-978, 2016

• DOI för Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation

Lipoprotein-Associated Phospholipase A(2) Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease

Wallentin, Lars; Held, Claes; Armstrong, Paul W.; Cannon, Christopher P. et al.

Ingår i Journal of the American Heart Association, 2016

• DOI för Lipoprotein-Associated Phospholipase A(2) Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease

Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin: results from the ARISTOTLE trial

Rao, P.; Alexander, J. H.; Wojdyla, D.; Atar, D. et al.

Ingår i EUROPEAN HEART JOURNAL, s. 233-234, 2016

Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial

Åkerblom, Axel; Clare, Robert M.; Lokhnygina, Yuliya; Wallentin, Lars et al.

Ingår i American Heart Journal, s. 1-8, 2016

• DOI för Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial

Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

Armaganijan, Luciana V.; Alexander, Karen P.; Huang, Zhen; Tricoci, Pierluigi et al.

Ingår i American Heart Journal, s. 176-184, 2016

• DOI för Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial

Kappetein, Arie Pieter; Serruys, Patrick W.; Sabik, Joseph F.; Leon, Martin B. et al.

Ingår i EuroIntervention, s. 861-872, 2016

• DOI för Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial

The ABC risk score for patients with atrial fibrillation Reply

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Siegbahn, Agneta et al.

Ingår i The Lancet, s. 1980-1981, 2016

Successful reperfusion is associated with lower levels of markers of myocardial damage and dysfunction in ST-elevation but not in non-ST-elevation myocardial infarction: insights from the PLATO trial

Varenhorst, Christoph; Åkerblom, Axel; Renlund, Henrik; Kunadian, V. et al.

Ingår i EUROPEAN HEART JOURNAL, s. 1282-1283, 2016

Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry

Sahlen, Anders; Varenhorst, Christoph; Lagerqvist, Bo; Renlund, Henrik et al.

Ingår i European Heart Journal, s. 3335-3342, 2016

• DOI för Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry
• Ladda ner fulltext (pdf) av Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry

Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome

Hess, Paul L.; Wojdyla, Daniel M.; Al-Khatib, Sana M.; Lokhnygina, Yuliya et al.

Ingår i JAMA cardiology, s. 73-79, 2016

• DOI för Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome

Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study

Wallentin, Lars; Lindhagen, Lars; Ärnström, Elisabet; Husted, Steen et al.

Ingår i The Lancet, s. 1903-1911, 2016

• DOI för Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study

Tooth Loss is Independently Associated with Poor Outcomes in Stable Coronary Heart Disease

Vedin, Ola; Hagström, Emil; Budaj, Andrzej; Denchev, Stephan et al.

Ingår i European Journal of Preventive Cardiology, s. 839-846, 2016

• DOI för Tooth Loss is Independently Associated with Poor Outcomes in Stable Coronary Heart Disease

Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial

Focks, Jeroen Jaspers; Brouwer, Marc A.; Wojdyla, Daniel M.; Thomas, Laine et al.

Ingår i BMJ-BRITISH MEDICAL JOURNAL, 2016

• DOI för Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial

Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases

Tajuddin, Salman M.; Schick, Ursula M.; Eicher, John D.; Chami, Nathalie et al.

Ingår i American Journal of Human Genetics, s. 22-39, 2016

• DOI för Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases

Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals

Eicher, John D.; Chami, Nathalie; Kacprowski, Tim; Nomura, Akihiro et al.

Ingår i American Journal of Human Genetics, s. 40-55, 2016

• DOI för Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals

Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits

Chami, Nathalie; Chen, Ming-Huei; Slater, Andrew J.; Eicher, John D. et al.

Ingår i American Journal of Human Genetics, s. 8-21, 2016

• DOI för Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits

Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome

Johansson, Åsa; Eriksson, Niclas; Lindholm, Daniel; Varenhorst, Christoph et al.

Ingår i Human Molecular Genetics, s. 1447-1456, 2016

• DOI för Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome

Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial

Vranckx, Pascal; White, Harvey D.; Huang, Zhen; Mahaffey, Kenneth W. et al.

Ingår i Journal of the American College of Cardiology, s. 2135-2144, 2016

• DOI för Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial

External Validation Of The Biomarker-Based ABC-Stroke Risk Score For Atrial Fibrillation

Oldgren, Jonas; Hijazi, Ziad; Lindbäck, Johan; Alexander, John et al.

Ingår i Journal of the American College of Cardiology, s. 879-879, 2016

Prediction Of Major Bleeding In Revascularized Patients With Acute Coronary Syndromes: Development Of A Novel Biomarker-Based Clinical Prediction Model

Lindholm, Daniel; Lindbäck, Johan; James, Stefan; Becker, Richard et al.

Ingår i Journal of the American College of Cardiology, s. 493-493, 2016

Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease

Stewart, Ralph A. H.; Wallentin, Lars; Benatar, Jocelyne; Danchin, Nicolas et al.

Ingår i European Heart Journal, s. 1993-2001, 2016

• DOI för Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease
• Ladda ner fulltext (pdf) av Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease

Renal Function in Atrial Fibrillation A Multifaceted Dilemma

Hijazi, Ziad; Wallentin, Lars

Ingår i Circulation, s. 48-51, 2016

• DOI för Renal Function in Atrial Fibrillation A Multifaceted Dilemma

Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease

De Caterina, Raffaele; Husted, Steen; Wallentin, Lars; Andreotti, Felicita et al.

Ingår i Thrombosis and Haemostasis, s. 685-711, 2016

• DOI för Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease

Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis Results From the TRACER Angiographic Substudy

Popma, Christopher J.; Sheng, Shi; Korjian, Serge; Daaboul, Yazan et al.

Ingår i Circulation. Cardiovascular Interventions, 2016

• DOI för Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis Results From the TRACER Angiographic Substudy

All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome

Batra, Gorav; Svennblad, Bodil; Held, Claes; Jernberg, Tomas et al.

Ingår i Heart, s. 926-933, 2016

• DOI för All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome

Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Shimada, Yuichi J.; Bansilal, Sameer; Wiviott, Stephen D.; Becker, Richard C. et al.

Ingår i American Heart Journal, s. 1-8, 2016

• DOI för Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Evaluation of Temporal Changes in Cardiovascular Biomarker Concentrations Improves Risk Prediction in an Elderly Population from the Community

Eggers, Kai M; Kempf, Tibor; Larsson, Anders; Lindahl, Bertil et al.

Ingår i Clinical Chemistry, s. 485-493, 2016

• DOI för Evaluation of Temporal Changes in Cardiovascular Biomarker Concentrations Improves Risk Prediction in an Elderly Population from the Community

Dabigatran etexilate and reduction in serum apolipoprotein B

Joseph, Philip; Pare, Guillaume; Wallentin, Lars; Connolly, Stuart et al.

Ingår i Heart, s. 57-62, 2016

• DOI för Dabigatran etexilate and reduction in serum apolipoprotein B

D-dimer and factor VIIa in atrial fibrillation: prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy

Siegbahn, Agneta; Oldgren, Jonas; Andersson, Ulrika; Ezekowitz, Michael D et al.

Ingår i Thrombosis and Haemostasis, s. 921-930, 2016

• DOI för D-dimer and factor VIIa in atrial fibrillation: prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy

Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study

Hagström, Emil; James, Stefan; Bertilsson, Maria; Becker, Richard C et al.

Ingår i European Heart Journal, s. 1325-1333, 2016

• DOI för Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study

Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial

Durheim, Michael T.; Cyr, Derek D.; Lopes, Renato D.; Thomas, Laine E. et al.

Ingår i International Journal of Cardiology, s. 589-594, 2016

• DOI för Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial

Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Bui, An H.; Cannon, Christopher P.; Steg, Philippe Gabriel; Storey, Robert F. et al.

Ingår i Circulation, 2016

• DOI för Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention

Velders, Matthijs A.; Abtan, Jeremie; Angiolillo, Dominick J.; Ardissino, Diego et al.

Ingår i Heart, s. 617-625, 2016

• DOI för Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention

Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation

Hijazi, Ziad; Aulin, Julia; Andersson, Ulrika; Alexander, John H. et al.

Ingår i Heart, s. 508-517, 2016

• DOI för Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation

Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial)

Erlinge, David; Koul, Sasha; Eriksson, Peter; Schersten, Fredrik et al.

Ingår i American Heart Journal, s. 36-46, 2016

• DOI för Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial)

History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial

De Caterina, Raffaele; Andersson, Ulrika; Alexander, John H.; Al-Khatib, Sana M. et al.

Ingår i American Heart Journal, s. 175-183, 2016

• DOI för History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
• Ladda ner fulltext (pdf) av History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial

Serum Uric Acid Is Associated With Cardiovascular Outcomes In Patients With Acute Coronary Syndromes: Results From The Platelet Inhibition And Patient Outcomes (Plato) Trial

Åkerblom, Axel; James, Stefan; Bertilsson, Maria; Himmelmann, Anders et al.

Ingår i Journal of the American College of Cardiology, s. 556-556, 2016

Time Based Measures Of Treatment Effect: Reassessment Of Ticagrelor Versus Clopidogrel In The Plato Study

James, Stefan K.; Bellavia, Andrea; Orsini, Nicola; Wallentin, Lars et al.

Ingår i Journal of the American College of Cardiology, s. 548-548, 2016

External Validation Of The Biomarker-Based ABC-Bleeding Risk Score For Atrial Fibrillation

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John et al.

Ingår i Journal of the American College of Cardiology, s. 893-893, 2016

Diabetes Mellitus And Cardiovascular Risk In Patients With Chronic Coronary Heart Disease

Sinnaeve, Peter R.; Hagström, Emil; Armstrong, Paul; Budaj, Andrzej et al.

Ingår i Journal of the American College of Cardiology, s. 2162-2162, 2016

The Relationship Between Tooth Loss, Cardiovascular Biomarkers And Outcomes In Patients With Stable Coronary Heart Disease

Vedin, Ola; Hagström, Emil; Östlund, Ollie; Avezum, Alvaro et al.

Ingår i Journal of the American College of Cardiology, s. 1969-1969, 2016

Self-Reported General Health And Outcomes In Patients With Stable Coronary Artery Disease: Experiences From The Global Stability Trial

Stewart, Ralph Alan Huston; Hagström, Emil; Held, Claes; Armstrong, Paul et al.

Ingår i Journal of the American College of Cardiology, s. 2113-2113, 2016

Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy

Eriksson, Niclas; Wallentin, Lars; Berglund, Lars; Axelsson, Tomas et al.

Ingår i Pharmacogenomics (London), s. 1425-1439, 2016

• DOI för Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy
• Ladda ner fulltext (pdf) av Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy

Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study

Wallentin, Lars; Lindhagen, Lars; Ärnström, Elisabet; Husted, Steen et al.

Ingår i The Lancet, s. 1903-1911, 2016

Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events

Majeed, Ammar; Hwang, Hun-Gyu; Eikelboom, John W.; Connolly, Stuart et al.

Ingår i Thrombosis Research, s. 81-88, 2016

• DOI för Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events

Commentary on the OPTIDUAL trial results: how to optimise prolonged dual antiplatelet treatment and independent randomised clinical trials.

Wallentin, Lars

Ingår i European Heart Journal, s. 375-377, 2016

• DOI för Commentary on the OPTIDUAL trial results: how to optimise prolonged dual antiplatelet treatment and independent randomised clinical trials.

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

Hijazi, Ziad; Lindbäck, Johan; Alexander, John H.; Hanna, Michael et al.

Ingår i European Heart Journal, s. 1582-1590, 2016

• DOI för The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Ingår i The Lancet, s. 2302-2311, 2016

• DOI för The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

Activated Leukocyte Cell Adhesion Molecule (ALCAM) And Outcomes In Acute Coronary Syndromes: A Plato Biomarker Substudy

Wallentin, Lars; Michelsen, Annika E.; Aukrust, Pal; Becker, Richard et al.

Ingår i Journal of the American College of Cardiology, 2015

• DOI för Activated Leukocyte Cell Adhesion Molecule (ALCAM) And Outcomes In Acute Coronary Syndromes: A Plato Biomarker Substudy

Growth Differentiation Factor-15 (GDF-15) For Prognostication Of Outcomes In Stable Coronary Artery Disease: Experiences From The Stability Trial

Wallentin, Lars; Held, Claes; Stewart, Ralph; Budaj, Andrzej et al.

Ingår i Journal of the American College of Cardiology, 2015

Tooth Loss Is Independently Associated With Adverse Outcome But Not Myocardial Infarction In Patients With Chronic Coronary Heart Disease

Vedin, Ola; Hagström, Emil; Budaj, Andrzej; Denchev, Stephan et al.

Ingår i Journal of the American College of Cardiology, 2015

Outcome In Relation To Antithrombotic Therapy After Myocardial Infarction And Percutaneous Coronary Intervention In Patients With Atrial Fibrillation

Batra, Gorav; Friberg, Leif; Erlinge, David; James, Stefan et al.

Ingår i Journal of the American College of Cardiology, 2015

• DOI för Outcome In Relation To Antithrombotic Therapy After Myocardial Infarction And Percutaneous Coronary Intervention In Patients With Atrial Fibrillation

Antithrombotic Medication And Outcomes After Myocardial Infarction In Patients With Atrial Fibrillation Not Undergoing Percutaneous Coronary Intervention

Batra, Gorav; Friberg, Leif; Erlinge, David; James, Stefan et al.

Ingår i Journal of the American College of Cardiology, 2015

• DOI för Antithrombotic Medication And Outcomes After Myocardial Infarction In Patients With Atrial Fibrillation Not Undergoing Percutaneous Coronary Intervention

Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial

Ezekowitz, Justin A.; Lewis, Basil S.; Lopes, Renato D.; Wojdyla, Daniel M. et al.

Ingår i European Heart Journal - Cardiovascular Pharmacotherapy, s. 86-94, 2015

• DOI för Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial

Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy

Janzon, M.; James, Stefan K.; Cannon, C. P.; Storey, R. F. et al.

Ingår i Heart, s. 119-125, 2015

• DOI för Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy
• Ladda ner fulltext (pdf) av Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy

NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO)

Johansson, Åsa; Eriksson, Niclas; Becker, Richard C.; Storey, Robert F. et al.

Ingår i Circulation, s. 498-506, 2015

• DOI för NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO)

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial

Brambatti, Michela; Darius, Harald; Oldgren, Jonas; Clemens, Andreas et al.

Ingår i International Journal of Cardiology, s. 127-131, 2015

• DOI för Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial

Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Kang, Hyun-Jae; Clare, Robert M.; Gao, Runlin; Held, Claes et al.

Ingår i American Heart Journal, s. 899-+, 2015

• DOI för Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial
• Ladda ner fulltext (pdf) av Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial

Boehm, Michael; Ezekowitz, Michael D.; Connolly, Stuart J.; Eikelboom, John W. et al.

Ingår i Journal of the American College of Cardiology, s. 2481-2493, 2015

• DOI för Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial

Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial

Velders, Matthijs A.; Wallentin, Lars; Becker, Richard C.; van Boven, Adrianus J. et al.

Ingår i American Heart Journal, s. 879-8890000000, 2015

• DOI för Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial
• Ladda ner fulltext (pdf) av Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial

Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial

Cornel, Jan H.; Lopes, Renato D.; James, Stefan; Stevens, Susanna R. et al.

Ingår i American Heart Journal, s. 531-538, 2015

• DOI för Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial

Economic Analysis of Ticagrelor Therapy From a U.S. Perspective: Results From the PLATO Study

Cowper, Patricia A; Pan, Wenqin; Anstrom, Kevin J; Kaul, Padma et al.

Ingår i Journal of the American College of Cardiology, s. 465-476, 2015

• DOI för Economic Analysis of Ticagrelor Therapy From a U.S. Perspective: Results From the PLATO Study

Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes

Mahaffey, Kenneth W.; Hager, Rebecca; Wojdyla, Daniel; White, Harvey D. et al.

Ingår i Journal of the American Heart Association, 2015

• DOI för Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes
• Ladda ner fulltext (pdf) av Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes

Bleeding and thromboembolic outcomes in warfarin-and dabigatran-treated patients in the RE-LY trial who required an urgent surgery or procedure

Douketis, J.; Healey, J. S.; Brueckmann, M.; Fraessdorf, M. et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 393-394, 2015

Comparison of hospital variation in acute myocardial infarction care and outcome between Sweden and United Kingdom: population based cohort study using nationwide clinical registries

Chung, Sheng-Chia; Sundström, Johan; Gale, Chris P.; James, Stefan K. et al.

Ingår i BMJ-BRITISH MEDICAL JOURNAL, 2015

• DOI för Comparison of hospital variation in acute myocardial infarction care and outcome between Sweden and United Kingdom: population based cohort study using nationwide clinical registries
• Ladda ner fulltext (pdf) av Comparison of hospital variation in acute myocardial infarction care and outcome between Sweden and United Kingdom: population based cohort study using nationwide clinical registries

Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure: Substudy of the RE-LY trial

Douketis, J D; Healey, J S; Brueckmann, M; Eikelboom, J W et al.

Ingår i Thrombosis and Haemostasis, s. 625-632, 2015

• DOI för Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure: Substudy of the RE-LY trial

Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)

Cornel, Jan H.; Tricoci, Pierluigi; Lokhnygina, Yuliya; Moliterno, David J. et al.

Ingår i American Journal of Cardiology, s. 1325-1332, 2015

• DOI för Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)

Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial

Westenbrink, B. D.; Alings, M.; Connolly, S. J.; Eikelboom, J. et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 699-707, 2015

• DOI för Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial

Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction

Szummer, K; Oldgren, Jonas; Lindhagen, Lars; Carrero, J J et al.

Ingår i Journal of the American Medical Association (JAMA), s. 707-716, 2015

• DOI för Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction

Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy

Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika; Lindahl, Bertil et al.

Ingår i Clinical Chemistry, s. 368-378, 2015

• DOI för Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy

Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial

Held, Claes; Hylek, Elaine M; Alexander, John H; Hanna, Michael et al.

Ingår i European Heart Journal, s. 1264-1272, 2015

• DOI för Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial

Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial

Patel, MR; Becker, RC; Wojdyla, DM; Emanuelsson, H et al.

Ingår i European Journal of Preventive Cardiology, s. 734-742, 2015

• DOI för Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial

Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial

Granger, CB; Lopes, RD; Hanna, Michael; Ansell, Jack et al.

Ingår i American Heart Journal, s. 25-30, 2015

• DOI för Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial

Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial

Ducrocq, Gregory; Schulte, P J; Becker, R C; Cannon, C P et al.

Ingår i EuroIntervention, s. 737-745, 2015

• DOI för Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial

Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors

Vedin, Ola; Hagström, Emil; Gallup, Dianne; Neely, Megan L et al.

Ingår i European Journal of Preventive Cardiology, s. 771-778, 2015

• DOI för Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors

Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes Insights From the APPRAISE-2 Trial

Hess, Connie N.; James, Stefan K.; Lopes, Renato D.; Wojdyla, Daniel M. et al.

Ingår i Journal of the American College of Cardiology, s. 777-787, 2015

• DOI för Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes Insights From the APPRAISE-2 Trial

Effect of genetic variations on ticagrelor plasma levels and clinical outcomes

Varenhorst, Christoph; Eriksson, Niclas; Johansson, Åsa; Barratt, Bryan J. et al.

Ingår i European Heart Journal, s. 1901-1912, 2015

• DOI för Effect of genetic variations on ticagrelor plasma levels and clinical outcomes

Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation Incidence, Risk Factors, and Outcomes

Bekwelem, Wobo; Connolly, Stuart J.; Halperin, Jonathan L.; Adabag, Selcuk et al.

Ingår i Circulation, s. 796-803, 2015

• DOI för Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation Incidence, Risk Factors, and Outcomes

Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome

Khan, Razi; Lopes, Renato D.; Neely, Megan L.; Stevens, Susanna R. et al.

Ingår i Heart, s. 1475-1484, 2015

• DOI för Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome

Characterization of cardiovascular endpoints, impact of event adjudication and effects of darapladib in the STABILITY trial

Held, Claes; White, H. D.; Stewart, R. A. H.; Davies, R. et al.

Ingår i European Heart Journal, s. 1104-1104, 2015

Effect of ivabradine on heart rate variability in patients with stable coronary artery disease

Stewart, R. A. H.; Armstrong, P. W.; Chiswell, K.; Hagström, Emil et al.

Ingår i European Heart Journal, s. 1088-1088, 2015

Digoxin use is associated with higher mortality among patients with atrial fibrillation with and without heart failure: insights from the ARISTOTLE trial

Rordorf, R.; De Ferrari, G. M.; Wojdyla, D.; De Caterina, R. et al.

Ingår i European Heart Journal, s. 1068-1068, 2015

Biomarker-based risk score for prediction of cardiovascular events in stable coronary heart disease - Experiences from the STABILITY biomarker substudy

Wallentin, Lars C.; Lindbäck, Johan; Held, Claes; Granger, C. B. et al.

Ingår i European Heart Journal, s. 1041-1042, 2015

Effect of time to interventional treatment on NSTE-ACS outcomes in PLATO

Pollack, C.; Diercks, D.; Husted, S.; James, Stefan K. et al.

Ingår i European Heart Journal, s. 519-520, 2015

Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial)

Nagarakanti, Rangadham; Wallentin, Lars; Noack, Herbert; Brueckmann, Martina et al.

Ingår i American Journal of Cardiology, s. 1204-1209, 2015

• DOI för Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial)

Management and clinical consequences of major bleeding in high-risk patients following an acute coronary syndrome. Is aspirin the problem?: Insights from the APPRAISE-2 trial

Hagström, Emil; Wojdyla, D.; Neely, M. L.; Stevens, S. R. et al.

Ingår i European Heart Journal, s. 861-862, 2015

Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial

Ezekowitz, M. D.; Connolly, S. J.; Fraessdorf, M.; Brueckmann, M. et al.

Ingår i European Heart Journal, s. 862-862, 2015

Balancing the risk of ischaemic and bleeding events in ACS

Ducrocq, G.; Schulte, P. J.; Budaj, A.; Cornel, J. H. et al.

Ingår i European Heart Journal, s. 860-861, 2015

External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation

Hijazi, Ziad; Lindbäck, Johan; Östlund, Olof Petter; Siegbahn, Agneta et al.

Ingår i European Heart Journal, s. 710-711, 2015

Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation: Insights from the ARISTOTLE trial

Hijazi, Ziad; Hohnloser, S. H.; Andersson, Ulrika; Alexander, J. H. et al.

Ingår i European Heart Journal, s. 339-339, 2015

Less non-major bleeding with apixaban versus warfarin among patients with atrial fibrillation: insights from the ARISTOTLE trial

Bahit, M. C.; Lopes, R. D.; Wojdyla, D. M.; Held, Claes et al.

Ingår i European Heart Journal, s. 338-339, 2015

Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation

Alexander, J.; Andersson, Ulrika; Lopes, R. D.; Hijazi, Ziad et al.

Ingår i European Heart Journal, s. 345-345, 2015

Biomarker-based prediction model for recurrent ischemic events in revascularised patients with acute coronary syndromes

Lindholm, Daniel; Lindback, Johan; James, Stefan K.; Becker, R. C. et al.

Ingår i European Heart Journal, s. 10-11, 2015

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Andell, Pontus; James, Stefan K.; Cannon, Christopher P.; Cyr, Derek D. et al.

Ingår i Journal of the American Heart Association, 2015

• DOI för Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
• Ladda ner fulltext (pdf) av Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis

Andreotti, Felicita; Rocca, Bianca; Husted, Steen; Ajjan, Ramzi A et al.

Ingår i European Heart Journal, s. 3238-+, 2015

• DOI för Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis

Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Rao, Meena P; Halvorsen, Sigrun; Wojdyla, Daniel; Thomas, Laine et al.

Ingår i Journal of the American Heart Association, 2015

• DOI för Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
• Ladda ner fulltext (pdf) av Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial

Vinereanu, Dragos; Stevens, Susanna R; Alexander, John H; Al-Khatib, Sana M et al.

Ingår i European Heart Journal, s. 3268-+, 2015

• DOI för Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial

Reply: Anticoagulant-Related Nephropathy

Böhm, Michael; Ezekowitz, Michael D; Connolly, Stuart J; Eikelboom, John W et al.

Ingår i Journal of the American College of Cardiology, s. 2682, 2015

• DOI för Reply: Anticoagulant-Related Nephropathy

Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery

van Diepen, Sean; Tricoci, Pierluigi; Podder, Mohua; Westerhout, Cynthia M et al.

Ingår i Journal of the American Heart Association, 2015

• DOI för Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery
• Ladda ner fulltext (pdf) av Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery

Therapeutic Hypothermia for the Treatment of Acute Myocardial Infarction-Combined Analysis of the RAPID MI-ICE and the CHILL-MI Trials

Erlinge, David; Gotberg, Matthias; Noc, Marko; Lang, Irene et al.

Ingår i Therapeutic Hypothermia and Temperature Management, s. 77-84, 2015

• DOI för Therapeutic Hypothermia for the Treatment of Acute Myocardial Infarction-Combined Analysis of the RAPID MI-ICE and the CHILL-MI Trials

Genome-Wide Association Study Identifies That the ABO Blood Group System Influences Interleukin-10 Levels and the Risk of Clinical Events in Patients with Acute Coronary Syndrome

Johansson, Åsa; Alfredsson, Jenny; Eriksson, Niclas; Wallentin, Lars et al.

Ingår i PLOS ONE, 2015

• DOI för Genome-Wide Association Study Identifies That the ABO Blood Group System Influences Interleukin-10 Levels and the Risk of Clinical Events in Patients with Acute Coronary Syndrome
• Ladda ner fulltext (pdf) av Genome-Wide Association Study Identifies That the ABO Blood Group System Influences Interleukin-10 Levels and the Risk of Clinical Events in Patients with Acute Coronary Syndrome

Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

Aulin, Julia; Siegbahn, Agneta; Hijazi, Ziad; Ezekowitz, Michael D. et al.

Ingår i American Heart Journal, s. 1151-1160, 2015

• DOI för Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

Post-hoc analyses of darapladib, an oral Lp-PLA(2) inhibitor, in phase III cardiovascular outcomes trials may inform investigation in diabetic macular edema

Williams, Rachel; Shearn, Shawn Patrick; Dowd, Michael; Cicconetti, Greg et al.

Ingår i Investigative Ophthalmology and Visual Science, 2015

Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization.

Bagai, Akshay; Huang, Zhen; Lokhnygina, Yuliya; Harrington, Robert A et al.

Ingår i Circulation. Cardiovascular Interventions, 2015

• DOI för Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization.

Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Goto, Shinya; Zhu, Jun; Liu, Lisheng; Oh, Byung-Hee et al.

Ingår i American Heart Journal, s. 303-309, 2014

• DOI för Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type

Camenzind, E; Boersma, E; Wijns, W; Mauri, L et al.

Ingår i European Heart Journal, s. 1932-1948, 2014

• DOI för Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type

High Sensitivity Troponin T and Risk Stratification in Patients with Atrial Fibrillation during Treatment with Apixaban or Warfarin

Hijazi, Ziad; Wallentin, Lars; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i Journal of the American College of Cardiology, s. 52-61, 2014

• DOI för High Sensitivity Troponin T and Risk Stratification in Patients with Atrial Fibrillation during Treatment with Apixaban or Warfarin

Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation: a RE-LY Substudy

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J. et al.

Ingår i Heart, s. 1193-1200, 2014

• DOI för Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation: a RE-LY Substudy

Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) Study

Åkerblom, Axel; Eriksson, Niclas; Wallentin, Lars; Siegbahn, Agneta et al.

Ingår i American Heart Journal, s. 96-102, 2014

• DOI för Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) Study

Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin

Hylek, Elaine M.; Held, Claes; Alexander, John H.; Lopes, Renato D. et al.

Ingår i Journal of the American College of Cardiology, s. 2141-2147, 2014

• DOI för Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Circulation, s. 961-970, 2014

• DOI för Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients With Chronic Stable Atherosclerosis

Mahaffey, Kenneth W.; Wojdyla, Daniel M.; Pieper, Karen S.; Tricoci, Pierluigi et al.

Ingår i Clinical Cardiology, s. 337-342, 2014

• DOI för Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients With Chronic Stable Atherosclerosis

Chemokine (CXC motif) ligand 16 (CXCL16) and osteoprotegerin (OPG) as predictors of outcome in patients with acute coronary syndromes (ACS) a PLATO biomarker substudy

Ueland, T.; Michelsen, A.; Aukrust, P.; Becker, R. et al.

Ingår i European Heart Journal, s. 486-486, 2014

ApoA1 is independently associated with recurrent ischemic events and death in acute coronary syndrome patients

Oskarsson, A.; Varenhorst, Christoph; Hagström, Emil; Wernroth, Mona-Lisa et al.

Ingår i European Heart Journal, s. 482-482, 2014

Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study

Storey, Robert F; James, Stefan K; Siegbahn, Agneta; Varenhorst, Christoph et al.

Ingår i Platelets, s. 517-525, 2014

• DOI för Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study

Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis"

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Circulation, 2014

• DOI för Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis"

Pentraxin 3 (PTX3) predict adverse outcome in acute coronary syndromes - a PLATO biomarker substudy

Kontny, F.; Ueland, T.; Aukrust, P.; Michelsen, A. E. et al.

Ingår i European Heart Journal, s. 319-319, 2014

A new biomarker based risk score for predicting major bleeding in atrial fibrillation - the ABC (age, biomarkers, current disease) risk score

Hijazi, Ziad; Lindbäck, Johan; Siegbahn, Agneta; Alexander, J. H. et al.

Ingår i European Heart Journal, s. 357-357, 2014

Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A substudy from the ARISTOTLE trial

Åsberg, S.; Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i European Heart Journal, s. 426-426, 2014

Secreted wingless (Wnt) antagonists and risk prediction in acute coronary syndrome (ACS) a PLATO biomarker substudy

Ueland, T.; Aukrust, P.; Michelsen, A.; Bertilsson, Maria et al.

Ingår i European Heart Journal, s. 318-318, 2014

The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial

Husted, Steen; James, Stefan K.; Bach, Richard G.; Becker, Richard C. et al.

Ingår i European Heart Journal, s. 1541-1550, 2014

• DOI för The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial
• Ladda ner fulltext (pdf) av The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial

Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER

White, Harvey D.; Huang, Zhen; Tricoci, Pierluigi; Van de Werf, Frans et al.

Ingår i Journal of the American Heart Association, 2014

• DOI för Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER

No misrepresentation of vital status follow-up in PLATO : Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: Challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014

Wallentin, Lars; Becker, Richard C.; Cannon, Christopher P.; Held, Claes et al.

Ingår i International Journal of Cardiology, s. 300-302, 2014

• DOI för No misrepresentation of vital status follow-up in PLATO : Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: Challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014

Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation Insights From the ARISTOTLE Trial

Flaker, Greg; Lopes, Renato D.; Hylek, Elaine; Wojdyla, Daniel M. et al.

Ingår i Journal of the American College of Cardiology, s. 1541-1550, 2014

• DOI för Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation Insights From the ARISTOTLE Trial

Impact of an invasive strategy on 5 years outcome in men and women with non-ST-segment elevation acute coronary syndromes

Alfredsson, Joakim; Clayton, Tim; Damman, Peter; Fox, Keith A. A. et al.

Ingår i American Heart Journal, s. 522-529, 2014

• DOI för Impact of an invasive strategy on 5 years outcome in men and women with non-ST-segment elevation acute coronary syndromes

How can we optimize the processes of care for acute coronary syndromes to improve outcomes?

Wallentin, Lars; Kristensen, Steen Dalby; Anderson, Jeffrey L.; Tubaro, Marco et al.

Ingår i American Heart Journal, s. 622-631, 2014

• DOI för How can we optimize the processes of care for acute coronary syndromes to improve outcomes?

Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?

Huber, Kurt; Bates, Eric R.; Valgimigli, Marco; Wallentin, Lars et al.

Ingår i American Heart Journal, s. 611-621, 2014

• DOI för Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?

Prognostic implication of the new peri-PCI (type 4a) myocardial infarction definition according to the third universal definition of myocardial infarction in patients with NSTE ACS

Tricoci, P.; Clare, R.; Leonardi, S.; White, H. D. et al.

Ingår i European Heart Journal, s. 138-138, 2014

The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment

Christersson, Christina; Wallentin, Lars; Andersson, Ulrika; Hylek, E. M. et al.

Ingår i European Heart Journal, s. 866-867, 2014

Efficacy and safety of ticagrelor in patients with acute coronary syndrome and heart failure: insights from the platelet inhibition and patient outcomes (PLATO) trial

Brito, F. S. B. De Souza; Åkerblom, Axel A.; Wojdyla, D. W.; Steg, P. G. S. et al.

Ingår i European Heart Journal, s. 202-203, 2014

Response to Letter Regarding Article, "Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin"

Majeed, Ammar; Hwang, Hun-Gyu; Connolly, Stuart J.; Eikelboom, John W. et al.

Ingår i Circulation, 2014

• DOI för Response to Letter Regarding Article, "Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin"

Response to Letter Regarding Article, "Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study"

Marijon, Eloi; Le Heuzey, Jean-Yves; Connolly, Stuart; Yang, Sean et al.

Ingår i Circulation, 2014

• DOI för Response to Letter Regarding Article, "Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study"

Usefulness and Safety of Vorapaxar in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)

Valgimigli, Marco; Tricoci, Pierluigi; Huang, Zhen; Aylward, Philip E. et al.

Ingår i American Journal of Cardiology, s. 665-673, 2014

• DOI för Usefulness and Safety of Vorapaxar in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)

D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation: observations from the ARISTOTLE trial

Christersson, Christina; Wallentin, Lars; Andersson, Ulrika; Alexander, J. H. et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 1401-1412, 2014

• DOI för D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation: observations from the ARISTOTLE trial

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial

Lindholm, Daniel; Varenhorst, Christoph; Cannon, Christopher P.; Harrington, Robert A. et al.

Ingår i European Heart Journal, s. 2083-2093, 2014

• DOI för Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial
• Ladda ner fulltext (pdf) av Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial

Reply: regarding the effect of dabigatran plasma concentrations

Reilly, Paul A; Connolly, Stuart J; Yusuf, S; Eikelboom, JW et al.

Ingår i Journal of the American College of Cardiology, s. 2885-2886, 2014

• DOI för Reply: regarding the effect of dabigatran plasma concentrations

The use of dabigatran according to body mass index: the RE-LY experience

Ezekowitz, M. E.; Parise, H.; Connolly, S. J.; Brueckmann, M. et al.

Ingår i European Heart Journal, s. 1111-1111, 2014

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

Halvorsen, Sigrun; Atar, Dan; Yang, Hongqiu; De Caterina, Raffaele et al.

Ingår i European Heart Journal, s. 1864-1872, 2014

• DOI för Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Mahaffey, Kenneth W.; Held, Claes; Wojdyla, Daniel M.; James, Stefan K. et al.

Ingår i Journal of the American College of Cardiology, s. 1493-1499, 2014

• DOI för Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries The RE-LY Atrial Fibrillation Registry

Oldgren, Jonas; Healey, Jeff S.; Ezekowitz, Michael; Commerford, Patrick et al.

Ingår i Circulation, s. 1568-1576, 2014

• DOI för Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries The RE-LY Atrial Fibrillation Registry

Association of cyclooxygenase-2 genetic variant with cardiovascular disease

Ross, Stephanie; Eikelboom, John; Anand, Sonia S.; Eriksson, Niclas et al.

Ingår i European Heart Journal, s. 2242-2248, 2014

• DOI för Association of cyclooxygenase-2 genetic variant with cardiovascular disease

Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark

Henriksson, Martin; Nikolic, Elisabet; Ohna, Audun; Wallentin, Lars et al.

Ingår i Scandinavian Cardiovascular Journal, s. 138-147, 2014

• DOI för Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark

Response to Letter Regarding Article, "Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial"

Steg, P. Gabriel; Harrington, Robert A.; Emanuelsson, Hakan; Katus, Hugo A. et al.

Ingår i Circulation, 2014

• DOI för Response to Letter Regarding Article, "Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial"

Management and clinical outcomes in patients treated with apixaban versus warfarin undergoing procedures

Garcia, David; Alexander, John H; Wallentin, Lars; Wojdyla, Daniel M et al.

Ingår i Blood, s. 3692-3698, 2014

• DOI för Management and clinical outcomes in patients treated with apixaban versus warfarin undergoing procedures

Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial

Held, Claes; Tricoci, Pierluigi; Huang, Zhen; Van de Werf, Frans et al.

Ingår i European Heart Journal, s. 246-256, 2014

• DOI för Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial

Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes

Varenhorst, Christoph; Alström, Ulrica; Braun, Oscar Ö; Storey, Robert F et al.

Ingår i Heart, s. 1762-1769, 2014

• DOI för Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes

Effect of Esomeprazole With/Without Acetylsalicylic Acid, Omeprazole and Lansoprazole on Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers

Andersson, Tommy; Nagy, Peter; Niazi, Mohammad; Nylander, Sven et al.

Ingår i American Journal of Cardiovascular Drugs, s. 217-227, 2014

• DOI för Effect of Esomeprazole With/Without Acetylsalicylic Acid, Omeprazole and Lansoprazole on Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers

Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial

Tricoci, Pierluigi; Lokhnygina, Yuliya; Huang, Zhen; Van de Werf, Frans et al.

Ingår i American Heart Journal, s. 869-8770, 2014

• DOI för Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial

Dabigatran versus warfarin in patients with pacemaker or defibrillator wires in the RE-LY trial: the role of contact activation

Ezekowitz, M. D.; Parise, H.; Noack, H.; Brueckmann, M. et al.

Ingår i European Heart Journal, s. 1115-1115, 2014

Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation

Aulin, Julia; Hijazi, Ziad; Andersson, Ulrika; Gersh, B. J. et al.

Ingår i European Heart Journal, s. 1115-1116, 2014

Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Wallentin, Lars; Hijazi, Ziad; Andersson, Ulrika; Alexander, John H. et al.

Ingår i Circulation, s. 1847-1858, 2014

• DOI för Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Rapid Endovascular Catheter Core Cooling Combined With Cold Saline as an Adjunct to Percutaneous Coronary Intervention for the Treatment of Acute Myocardial Infarction The CHILL-MI Trial: A Randomized Controlled Study of the Use of Central Venous Catheter Core Cooling Combined With Cold Saline as an Adjunct to Percutaneous Coronary Intervention for the Treatment of Acute Myocardial Infarction

Erlinge, David; Gotberg, Matthias; Lang, Irene; Holzer, Michael et al.

Ingår i Journal of the American College of Cardiology, s. 1857-1865, 2014

• DOI för Rapid Endovascular Catheter Core Cooling Combined With Cold Saline as an Adjunct to Percutaneous Coronary Intervention for the Treatment of Acute Myocardial Infarction The CHILL-MI Trial: A Randomized Controlled Study of the Use of Central Venous Catheter Core Cooling Combined With Cold Saline as an Adjunct to Percutaneous Coronary Intervention for the Treatment of Acute Myocardial Infarction

Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value

Wallentin, Lars; Himmelmann, Anders; Storey, Robert F.; Steg, Philippe Gabriel et al.

Ingår i Thrombosis and Haemostasis, s. 12-14, 2014

• DOI för Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value

Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013

Wallentin, Lars; Becker, Richard C.; Cannon, Christopher P.; Held, Claes et al.

Ingår i International Journal of Cardiology, 2014

• DOI för Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013

Management of dyspepsia symptoms on dabigatran during RELY-ABLE: a long-term follow up of RE-LY patients.

Reilly, Paul; Nieuwlaat, Robby; Healey, Jeff; Formella, Stephan et al.

Ingår i Pharmacotherapy, 2014

Response to Letter Regarding Article, "Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation"

Wallentin, Lars; Lopes, Renato D.; Hanna, Michael; Thomas, Laine et al.

Ingår i Circulation, 2014

• DOI för Response to Letter Regarding Article, "Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation"

Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery

Whellan, David J.; Tricoci, Pierluigi; Chen, Edmond; Huang, Zhen et al.

Ingår i Journal of the American College of Cardiology, s. 1048-1057, 2014

• DOI för Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery

Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)

Mahaffey, Kenneth W.; Huang, Zhen; Wallentin, Lars; Storey, Robert F. et al.

Ingår i American Journal of Cardiology, s. 936-944, 2014

• DOI för Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)

Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK

Chung, Sheng-Chia; Gedeborg, Rolf; Nicholas, Owen; James, Stefan K. et al.

Ingår i The Lancet, s. 1305-1312, 2014

• DOI för Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK
• Ladda ner fulltext (pdf) av Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK

High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika; Granger, Christopher B. et al.

Ingår i Circulation, s. 625-634, 2014

• DOI för High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study)

Verdecchia, Paolo; Reboldi, Gianpaolo; Di Pasquale, Giuseppe; Mazzotta, Giovanni et al.

Ingår i American Journal of Cardiology, s. 669-675, 2014

• DOI för Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study)

Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial

Alexander, John H.; Lopes, Renato D.; Thomas, Laine; Alings, Marco et al.

Ingår i European Heart Journal, s. 224-232, 2014

• DOI för Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial

The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)

Reilly, Paul A.; Lehr, Thorsten; Haertter, Sebastian; Connolly, Stuart J. et al.

Ingår i Journal of the American College of Cardiology, s. 321-328, 2014

• DOI för The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)

Darapladib for preventing ischemic events in stable coronary heart disease

White, Harvey D; Held, Claes; Stewart, Ralph; Tarka, Elizabeth et al.

Ingår i New England Journal of Medicine, s. 1702-1711, 2014

• DOI för Darapladib for preventing ischemic events in stable coronary heart disease

Additional Events in the RE-LY Trial

Connolly, Stuart J.; Wallentin, Lars; Yusuf, Salim

Ingår i New England Journal of Medicine, s. 1464-1465, 2014

• DOI för Additional Events in the RE-LY Trial

Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

Wallentin, Lars; Lindholm, Daniel; Siegbahn, Agneta; Wernroth, Lisa et al.

Ingår i Circulation, s. 293-303, 2014

• DOI för Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

Physical activity in patients with stable coronary heart disease: an international perspective

Stewart, Ralph; Held, Claes; Brown, Rebekkah; Vedin, Ola et al.

Ingår i European Heart Journal, s. 3286-3293, 2013

• DOI för Physical activity in patients with stable coronary heart disease: an international perspective

Large-scale association analysis identifies new risk loci for coronary artery disease

C. ARDIoGRAMplusC4D, Consortium; Wallentin, Lars

Ingår i Nature Genetics, s. 25-33, 2013

• DOI för Large-scale association analysis identifies new risk loci for coronary artery disease

Tooth loss is highly prevalent and associated with cardiovascular risk factors in patients with chronic coronary heart disease in the global stability trial

Vedin, Ola; Hagström, Emil; Gallup, Dianne; Neely, Megan et al.

Ingår i Journal of the American College of Cardiology, 2013

• DOI för Tooth loss is highly prevalent and associated with cardiovascular risk factors in patients with chronic coronary heart disease in the global stability trial

N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation: Insights from the ARISTOTLE trial

Hijazi, Ziad; Wallentin, Lars; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i Journal of the American College of Cardiology, s. 2274-2284, 2013

• DOI för N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation: Insights from the ARISTOTLE trial

Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study

Vedin, Ola; Hagström, Emil; Stewart, Ralph; Brown, Rebekkah et al.

Ingår i European Journal of Preventive Cardiology, s. 678-685, 2013

• DOI för Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study

Biomarkers in atrial fibrillation: a clinical review

Hijazi, Ziad; Oldgren, Jonas; Siegbahn, Agneta; Granger, Christopher B et al.

Ingår i European Heart Journal, s. 1475-1480, 2013

• DOI för Biomarkers in atrial fibrillation: a clinical review

Cystatin C- and Creatinine-based Estimates of Renal Function and Their Value for Risk Prediction in Patients with Acute Coronary Syndrome: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) Study

Åkerblom, Axel; Wallentin, Lars; Larsson, Anders; Siegbahn, Agneta et al.

Ingår i Clinical Chemistry, s. 1369-1375, 2013

• DOI för Cystatin C- and Creatinine-based Estimates of Renal Function and Their Value for Risk Prediction in Patients with Acute Coronary Syndrome: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) Study

Vitamin K antagonists in heart disease: Current status and perspectives (Section III)

De Caterina, Raffaele; Husted, Steen; Wallentin, Lars; Andreotti, Felicita et al.

Ingår i Thrombosis and Haemostasis, s. 1087-1107, 2013

• DOI för Vitamin K antagonists in heart disease: Current status and perspectives (Section III)

General mechanisms of coagulation and targets of anticoagulants (Section I): Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease

De Caterina, R; Husted, S; Wallentin, Lars; Andreotti, F et al.

Ingår i Thrombosis and Haemostasis, s. 569-579, 2013

• DOI för General mechanisms of coagulation and targets of anticoagulants (Section I): Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease

Parenteral anticoagulants in heart disease: Current status and perspectives (Section II) Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease

De Caterina, Raffaele; Husted, Steen; Wallentin, Lars; Andreotti, Felicita et al.

Ingår i Thrombosis and Haemostasis, s. 769-786, 2013

• DOI för Parenteral anticoagulants in heart disease: Current status and perspectives (Section II) Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease

Differences between acute myocardial infarction and unstable angina: a longitudinal cohort study reporting findings from the Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA)

Dudas, Kerstin; Björck, Lena; Jernberg, Tomas; Lappas, Georgios et al.

Ingår i BMJ Open, 2013

• DOI för Differences between acute myocardial infarction and unstable angina: a longitudinal cohort study reporting findings from the Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA)

Common variants associated with plasma triglycerides and risk for coronary artery disease

Do, Ron; Willer, Cristen J.; Schmidt, Ellen M.; Sengupta, Sebanti et al.

Ingår i Nature Genetics, s. 1345-+, 2013

• DOI för Common variants associated with plasma triglycerides and risk for coronary artery disease

Discovery and refinement of loci associated with lipid levels

Willer, Cristen J.; Schmidt, Ellen M.; Sengupta, Sebanti; Peloso, Gina M. et al.

Ingår i Nature Genetics, s. 1274-1283, 2013

• DOI för Discovery and refinement of loci associated with lipid levels

Undertreatment of elderly patients > 80-years with acute coronary syndrome despite high risk and similar benefits from evidence-based treatment as at younger age: results from SVEDEHEART

Held, Claes; Johanson, Per; Edberg, Annika; Bergström, Olle et al.

Ingår i Journal of the American College of Cardiology, 2013

• DOI för Undertreatment of elderly patients > 80-years with acute coronary syndrome despite high risk and similar benefits from evidence-based treatment as at younger age: results from SVEDEHEART

Change in Growth Differentiation Factor 15 Concentrations Over Time Independently Predicts Mortality in Community-Dwelling Elderly Individuals

Eggers, Kai M; Kempf, Tibor; Wallentin, Lars; Wollert, Kai C et al.

Ingår i Clinical Chemistry, s. 1091-1098, 2013

• DOI för Change in Growth Differentiation Factor 15 Concentrations Over Time Independently Predicts Mortality in Community-Dwelling Elderly Individuals

Are There Any Causal Relations Between Growth Differentiation Factor 15 and Outcomes in Patients With Acute Coronary Syndrome?: - A Report From the Plato Gwas Study

Hagström, Emil; Eriksson, Niclas; Johansson, Åsa; Bertilsson, Maria et al.

Ingår i Circulation, 2013

GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men

Wallentin, Lars; Zethelius, Bjorn; Berglund, Lars; Eggers, Kai M. et al.

Ingår i PLOS ONE, 2013

• DOI för GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men
• Ladda ner fulltext (pdf) av GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men

Evaluation of the Effect of Interleukin 18 Associated Genetic Polymorphisms on Risk of Cardiovascular Events in Patients With Acute Coronary Syndrome

Siegbahn, Agneta; Johansson, Åsa; Eriksson, Niclas; Hagström, Emil et al.

Ingår i Circulation, 2013

Large-scale association analysis identifies new risk loci for coronary artery disease

Deloukas, Panos; Kanoni, Stavroula; Willenborg, Christina; Farrall, Martin et al.

Ingår i Nature Genetics, s. 25-33, 2013

• DOI för Large-scale association analysis identifies new risk loci for coronary artery disease

Genetic Polymorphism and Relationship to Cystatin C Concentrations and Outcome - Results From the Platelet Inhibition and Patient Outcomes Study

Åkerblom, Axel; Wallentin, Lars; Siegbahn, Agneta; Becker, Richard C. et al.

Ingår i Circulation, 2013

Recurrent Events and Mortality Among Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the RE-LY Trial

Diener, H. C.; Marijon, E.; Le Heuzey, J. -Y; Connolly, S. et al.

Ingår i Cerebrovascular Diseases, s. 165-165, 2013

Clinical Outcomes of Patients with Previous Transient Ischaemic Attack or Stroke - a Subgroup Analysis of the Long-Term Extension of Dabigatran in Patients with Atrial Fibrillation (RELY-ABLE) Study

Diener, H. -C; Wallentin, Lars; Brueckmann, M.; Noack, H. et al.

Ingår i Cerebrovascular Diseases, s. 121-121, 2013

Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial

Cecilia Bahit, Maria; Lopes, Renato D.; Wojdyla, Daniel M.; Hohnloser, Stefan H. et al.

Ingår i International Journal of Cardiology, s. 215-220, 2013

• DOI för Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial

Use of apixaban and warfarin in patients undergoing invasive procedures: insights from ARISTOTLE

Lopes, R. D.; Garcia, D. A.; Wojdyla, D.; Dorian, P. et al.

Ingår i European Heart Journal, s. 98-99, 2013

• DOI för Use of apixaban and warfarin in patients undergoing invasive procedures: insights from ARISTOTLE

Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial

Held, Claes; Hylek, E. B.; Alexander, J. H.; Hanna, M. et al.

Ingår i European Heart Journal, s. 99-99, 2013

• DOI för Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial

Clinical validation of BARC definitions of bleeding after an ACS in the TRACER trial

Vranckx, P.; Tricoci, P.; Huang, Z.; Van de Werf, F. et al.

Ingår i European Heart Journal, s. 23-24, 2013

• DOI för Clinical validation of BARC definitions of bleeding after an ACS in the TRACER trial

Intracranial hemorrhage in acute coronary syndrome: incidence, predictors, and outcomes from APPRAISE-2, PLATO, and TRACER

Mahaffey, K. W.; Horton, J.; Alexander, J. H.; Tricoci, P. et al.

Ingår i European Heart Journal, s. 23-23, 2013

• DOI för Intracranial hemorrhage in acute coronary syndrome: incidence, predictors, and outcomes from APPRAISE-2, PLATO, and TRACER

Difference in causes of death between ticagrelor and clopidogrel in the PLATO trial

Varenhorst, Christoph; Alström, Ulrica; Braun, O. O.; Storey, R. F. et al.

Ingår i European Heart Journal, s. 827-827, 2013

• DOI för Difference in causes of death between ticagrelor and clopidogrel in the PLATO trial

Management of dyspepsia symptoms on dabigatran during RELY-ABLE: long-term follow up study after RE-LY

Nieuwlaat, R.; Healey, J. S.; Ezekowitz, M.; Reilly, P. et al.

Ingår i European Heart Journal, s. 102-102, 2013

• DOI för Management of dyspepsia symptoms on dabigatran during RELY-ABLE: long-term follow up study after RE-LY

GDF-15 level in acute coronary syndrome and its relations to cardiovascular risk factors, disease manifestations, treatments and outcome - results from the PLATO-study

Wallentin, Lars; Bertilsson, Maria; Becker, R. C.; Himmelmann, A. et al.

Ingår i European Heart Journal, s. 733-733, 2013

• DOI för GDF-15 level in acute coronary syndrome and its relations to cardiovascular risk factors, disease manifestations, treatments and outcome - results from the PLATO-study

Ischaemic events following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study

Storey, R. F.; Ardissino, D.; Vignali, L.; Cairns, R. et al.

Ingår i European Heart Journal, s. 826-826, 2013

• DOI för Ischaemic events following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study

ADMA and SDMA predict outcomes in patients with chronic atrial fibrillation: an ARISTOTLE substudy

Horowitz, J. D.; De Caterina, R.; Heresztyn, T.; Andersson, Ulrika et al.

Ingår i European Heart Journal, s. 1040-1041, 2013

• DOI för ADMA and SDMA predict outcomes in patients with chronic atrial fibrillation: an ARISTOTLE substudy

Health economic evaluation of ticagrelor compared to generic clopidogrel in patients with acute coronary syndromes intended for non-invasive management based on the PLATO trial

James, Stefan; Storey, R. F.; Cannon, C.; Janzon, M. et al.

Ingår i European Heart Journal, s. 896-896, 2013

• DOI för Health economic evaluation of ticagrelor compared to generic clopidogrel in patients with acute coronary syndromes intended for non-invasive management based on the PLATO trial

Reduction in recurrent ischemic events with vorapaxar: results from TRACER

White, H. D.; Huang, Z.; Tricoci, P.; Van De Werf, F. et al.

Ingår i European Heart Journal, s. 880-880, 2013

• DOI för Reduction in recurrent ischemic events with vorapaxar: results from TRACER

Efficacy and safety of apixaban compared with warfarin for stroke prevention in atrial fibrillation in East Asia

Goto, S.; Zhu, J.; Lisheng, L.; Oh, B. H. et al.

Ingår i European Heart Journal, s. 1039-1039, 2013

• DOI för Efficacy and safety of apixaban compared with warfarin for stroke prevention in atrial fibrillation in East Asia

High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men

Eggers, Kai M.; Al-Shakarchi, Jinan; Berglund, Lars; Lindahl, Bertil et al.

Ingår i American Heart Journal, s. 541-+, 2013

• DOI för High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men

Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATelet inhibition and patient outcomes (PLATO) trial

Brilakis, Emmanouil S.; Held, Claes; Meier, Bernhard; Cools, Frank et al.

Ingår i American Heart Journal, s. 474-480, 2013

• DOI för Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATelet inhibition and patient outcomes (PLATO) trial

Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial

Steg, P. Gabriel; Harrington, Robert A.; Emanuelsson, Hakan; Katus, Hugo A. et al.

Ingår i Circulation, s. 1055-1065, 2013

• DOI för Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial

Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial

Garcia, David A.; Wallentin, Lars; Lopes, Renato D.; Thomas, Laine et al.

Ingår i American Heart Journal, s. 549-558, 2013

• DOI för Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial

Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial

Al-Khatib, Sana M.; Thomas, Laine; Wallentin, Lars; Lopes, Renato D. et al.

Ingår i European Heart Journal, s. 2464-2471, 2013

• DOI för Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial

Quantitative ST-depression in Acute Coronary Syndromes: the PLATO Electrocardiographic Substudy

Armstrong, Paul W.; Westerhout, Cynthia M.; Fu, Yuling; Harrington, Robert A. et al.

Ingår i American Journal of Medicine, s. 723-+, 2013

• DOI för Quantitative ST-depression in Acute Coronary Syndromes: the PLATO Electrocardiographic Substudy

Health-Related Quality of Life of Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes-Results from the PLATO Trial

Levin, Lars-Ake; Wallentin, Lars; Bernfort, Lars; Andersson, David et al.

Ingår i Value in Health, s. 574-580, 2013

• DOI för Health-Related Quality of Life of Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes-Results from the PLATO Trial

Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation

Wallentin, Lars; Lopes, Renato D; Hanna, Michael; Thomas, Laine et al.

Ingår i Circulation, s. 2166-2176, 2013

• DOI för Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

Connolly, Stuart J.; Wallentin, Lars; Ezekowitz, Michael D.; Eikelboom, John et al.

Ingår i Circulation, s. 237-243, 2013

• DOI för The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

Ticagrelor versus clopidogrel in patients with non-st-elevation acute coronary syndrome: results from the PLATO trial

Lindholm, Daniel; Varenhorst, Christoph; Cannon, Christopher; Harrington, Robert et al.

Ingår i Journal of the American College of Cardiology, 2013

• DOI för Ticagrelor versus clopidogrel in patients with non-st-elevation acute coronary syndrome: results from the PLATO trial

The efficacy and safety of ticagrelor as compared to clopidogrel, with and without a glycoprotein iib/iia inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a PLATO (study of platelet inhibition and patient outcomes) analysis

Bansilal, Sameer; Wiviott, Stephen; Becker, Richard; Harrington, Robert et al.

Ingår i Journal of the American College of Cardiology, 2013

• DOI för The efficacy and safety of ticagrelor as compared to clopidogrel, with and without a glycoprotein iib/iia inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a PLATO (study of platelet inhibition and patient outcomes) analysis

Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST: Grupo de Trabajo para el manejo del infarto agudo de miocardio con elevación del segmento ST de la Sociedad Europea de Cardiología (ESC)

Steg, Gabriel; James, Stefan K; Atar, Dan; Badano, Luigi P et al.

Ingår i Revista Española de Cardiología, s. 530-5.3e+47, 2013

• DOI för Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST: Grupo de Trabajo para el manejo del infarto agudo de miocardio con elevación del segmento ST de la Sociedad Europea de Cardiología (ESC)

Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial

Leonardi, Sergio; Tricoci, Pierluigi; White, Harvey D; Armstrong, Paul W et al.

Ingår i European Heart Journal, s. 1723-1731, 2013

• DOI för Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial

"Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial" Response

Healey, Jeff S.; Eikelboom, John; Yang, Sean; Themeles, Ellison et al.

Ingår i Circulation, 2013

• DOI för "Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial" Response

International differences in treatment effect: do they really exist and why?

Pocock, Stuart; Calvo, Gonzalo; Marrugat, Jaume; Prasad, Krishna et al.

Ingår i European Heart Journal, s. 1846-1852, 2013

• DOI för International differences in treatment effect: do they really exist and why?

Prognostic relevance of PCI-related myocardial infarction

Woudstra, Pier; Grundeken, Maik J; van de Hoef, Tim P; Wallentin, Lars et al.

Ingår i Nature Reviews Cardiology, s. 231-236, 2013

• DOI för Prognostic relevance of PCI-related myocardial infarction

New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis

Oldgren, Jonas; Wallentin, Lars; Alexander, John H; James, Stefan et al.

Ingår i European Heart Journal, s. 1670-1680, 2013

• DOI för New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis
• Ladda ner fulltext (pdf) av New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis

Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding

Paré, Guillaume; Eriksson, Niclas; Lehr, Thorsten; Connolly, Stuart et al.

Ingår i Circulation, s. 1404, 2013

• DOI för Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding

Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy"

Hijazi, Ziad; Oldgren, Jonas; Wallentin, Lars; Andersson, Ulrika et al.

Ingår i Circulation, 2013

• DOI för Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy"

Ticagrelor in Patients With Acute Coronary Syndromes and Stroke Interpretation of Subgroups in Clinical Trials

James, Stefan K.; Pieper, Karen S.; Cannon, Christopher P.; Storey, Robert F. et al.

Ingår i Stroke, s. 1477-1479, 2013

• DOI för Ticagrelor in Patients With Acute Coronary Syndromes and Stroke Interpretation of Subgroups in Clinical Trials

Outcomes with ticagrelor versus clopidogrel in relation to high sensitivity troponin-T in non-ST-elevation acute coronary syndrome patients managed with early invasive or non-invasive treatment: a substudy from the prospective randomized PLATelet inhibit

Wallentin, Lars; James, Stefan; Giannitsis, Evangelos; Katus, Hugo et al.

Ingår i Pharmacotherapy, 2013

Reply: Higher N-Terminal Pro-B-Type Natriuretic Peptide May Be Related to Very Different Conditions

Hijazi, Ziad; Granger, Christopher B.; Wallentin, Lars

Ingår i Journal of the American College of Cardiology, s. 1635-1636, 2013

• DOI för Reply: Higher N-Terminal Pro-B-Type Natriuretic Peptide May Be Related to Very Different Conditions

Documentation of study medication dispensing in a prospective large randomized clinical trial: Experiences from the ARISTOTLE Trial

Alexander, John H.; Levy, Elliott; Lawrence, Jack; Hanna, Michael et al.

Ingår i American Heart Journal, s. 559-+, 2013

• DOI för Documentation of study medication dispensing in a prospective large randomized clinical trial: Experiences from the ARISTOTLE Trial

Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation

Eikelboom, John W.; Connolly, Stuart J.; Hart, Robert G.; Wallentin, Lars et al.

Ingår i Journal of the American College of Cardiology, s. 900-908, 2013

• DOI för Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation

Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial

Ferreira, Jorge; Ezekowitz, Michael D.; Connolly, Stuart J.; Brueckmann, Martina et al.

Ingår i European Journal of Heart Failure, s. 1053-1061, 2013

• DOI för Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial

Causes of Death and Influencing Factors in Patients With Atrial Fibrillation A Competing-Risk Analysis From the Randomized Evaluation of Long- Term Anticoagulant Therapy Study

Marijon, Eloi; Le Heuzey, Jean-Yves; Connolly, Stuart; Yang, Sean et al.

Ingår i Circulation, s. 2192-2201, 2013

• DOI för Causes of Death and Influencing Factors in Patients With Atrial Fibrillation A Competing-Risk Analysis From the Randomized Evaluation of Long- Term Anticoagulant Therapy Study

Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY®) Trial

Dans, Antonio L; Connolly, Stuart J; Wallentin, Lars; Yang, Sean et al.

Ingår i Circulation, s. 634-640, 2013

• DOI för Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY®) Trial

Reduction in First and Recurrent Cardiovascular Events with Ticagrelor Compared with Clopidogrel in the PLATO Study

Kohli, Payal; Wallentin, Lars; Reyes, Eric; Horrow, Jay et al.

Ingår i Circulation, s. 673, 2013

• DOI för Reduction in First and Recurrent Cardiovascular Events with Ticagrelor Compared with Clopidogrel in the PLATO Study

Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study

Nikolic, Elisabet; Janzon, Magnus; Hauch, Ole; Wallentin, Lars et al.

Ingår i European Heart Journal, s. 220-228, 2013

• DOI för Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study

Differential Prognostic Implications of Peak Troponin Level in Acute Coronary Syndrome Treated With and Without Revascularization

Bagai, Akshay; Huang, Zhen; Lokhnygina, Yuliya; Harrington, Robert A. et al.

Ingår i Circulation, 2013

RE-LY and RELY-ABLE: Long-term Follow-up of Patients With Non-valvular Atrial Fibrillation Receiving Dabigatran Etexilate for Up to 6.7 Years

Ezekowitz, Michael D.; Kent, Anthony P.; Pogue, Janice; Reilly, Paul A. et al.

Ingår i Circulation, 2013

Net Clinical Benefits of Ticagrelor Compared With Clopidogrel in Asian Acute Coronary Syndrome Patients: A Plato Sub-Study

Kang, Hyun-Jae; Clare, Robert M.; Gao, Runlin; Himmelmann, Anders et al.

Ingår i Circulation, 2013

Benefits of Dabigatran versus Warfarin in Hypertensive Patients With Atrial Fibrillation: Results From The Re-ly Trial

Nagarakanti, Rangadham; Connolly, Stuart; Brueckmann, Martina; Hart, Robert G. et al.

Ingår i Circulation, 2013

Efficacy and Safety of Vorapaxar in Elderly Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Insights From the TRACER Trial

Armaganijan, Luciana; Lopes, Renato; Huang, Zhen; Tricoci, Pierluigi et al.

Ingår i Circulation, 2013

CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS: Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial

Tricoci, Pierluigi; Chen, Edmond; Neely, Megan L.; Warner, Amelia et al.

Ingår i Circulation, 2013

Efficacy and Safety of Apixaban in Patients With Atrial Fibrillation According to Sex: Results From the ARISTOTLE Trial

Vinereanu, Dragos; Stevens, Susanna R.; Alexander, John H.; Al-Khatib, Sana M. et al.

Ingår i Circulation, 2013

Trends in Reperfusion Strategy 1995-2011 in Sweden. Results From the SWEDEHEART Registry

Held, Claes; Johanson, Per; Edberg, Annika; Mattsson, Eva et al.

Ingår i Circulation, 2013

Combining High Sensitivity Troponin I and T Measurements Improves Prediction of Long-Term Clinical Outcomes in Patients With Atrial Fibrillation - An Aristotle Substudy

Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika; Granger, Christopher B. et al.

Ingår i Circulation, 2013

Dabigatran Versus Warfarin Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation

Hori, Masatsugu; Connolly, Stuart J.; Zhu, Jun; Liu, Li Sheng et al.

Ingår i Stroke, s. 1891-+, 2013

• DOI för Dabigatran Versus Warfarin Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation

Response to Letter Regarding Article, "Ticagrelor in Patients With Acute Coronary Syndromes and Stroke: Interpretation of Subgroups in Clinical Trials"

James, Stefan K.; Storey, Robert F.; Pieper, Karen S.; Cannon, Christopher P. et al.

Ingår i Stroke, 2013

• DOI för Response to Letter Regarding Article, "Ticagrelor in Patients With Acute Coronary Syndromes and Stroke: Interpretation of Subgroups in Clinical Trials"

Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin

Majeed, Ammar; Hwang, Hun-Gyu; Connolly, Stuart J.; Eikelboom, John W. et al.

Ingår i Circulation, s. 2325-2332, 2013

• DOI för Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin

Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation Insights From the ARISTOTLE Trial

McMurray, John J. V.; Ezekowitz, Justin A.; Lewis, Basil S.; Gersh, Bernard J. et al.

Ingår i Circulation Heart Failure, s. 451-460, 2013

• DOI för Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation Insights From the ARISTOTLE Trial

Response to letters regarding article: “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial"

Healey, Jeff S; Eikelboom, John; Yang, Sean; Themeles, Ellison et al.

Ingår i Circulation, 2013

• DOI för Response to letters regarding article: “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial"

Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes)

Kunadian, Vijay; James, Stefan K.; Wojdyla, Daniel M.; Zorkun, Cafer et al.

Ingår i JACC-CARDIOVASCULAR INTERVENTIONS, s. 671-683, 2013

• DOI för Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes)

Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial

Van Spall, H G; Wallentin, Lars; Yusuf, S; Eikelboom, J W et al.

Ingår i Circulation, s. 2309-2316, 2012

• DOI för Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial

Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3 (FIR) trials

Damman, Peter; Clayton, Tim; Wallentin, Lars; Lagerqvist, Bo et al.

Ingår i Heart, s. 207-213, 2012

• DOI för Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3 (FIR) trials

Usefulness of the Admission Electrocardiogram to Predict Long-Term Outcomes After Non-ST-Elevation Acute Coronary Syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials)

Damman, Peter; Holmvang, Lene; Tijssen, Jan G P; Lagerqvist, Bo et al.

Ingår i American Journal of Cardiology, s. 6-12, 2012

• DOI för Usefulness of the Admission Electrocardiogram to Predict Long-Term Outcomes After Non-ST-Elevation Acute Coronary Syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials)

Long-Term Cardiovascular Mortality after Procedure-Related or Spontaneous Myocardial Infarction in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome: A Collaborative Analysis of Individual Patient Data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)

Damman, Peter; Wallentin, Lars; Fox, Keith A. A.; Windhausen, Fons et al.

Ingår i Circulation, s. 568-576, 2012

• DOI för Long-Term Cardiovascular Mortality after Procedure-Related or Spontaneous Myocardial Infarction in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome: A Collaborative Analysis of Individual Patient Data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

Tricoci, Pierluigi; Huang, Zhen; Held, Claes; Moliterno, David J et al.

Ingår i New England Journal of Medicine, s. 20-33, 2012

• DOI för Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J. et al.

Ingår i Circulation, s. 1605-1616, 2012

• DOI för Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Cystatin C and Estimated Glomerular Filtration Rate as Predictors for Adverse Outcome in Patients with ST-Elevation and Non-ST-Elevation Acute Coronary Syndromes: Results from the Platelet Inhibition and Patient Outcomes Study

Åkerblom, Axel; Wallentin, Lars; Siegbahn, Agneta; Becker, Richard C et al.

Ingår i Clinical Chemistry, s. 190-199, 2012

• DOI för Cystatin C and Estimated Glomerular Filtration Rate as Predictors for Adverse Outcome in Patients with ST-Elevation and Non-ST-Elevation Acute Coronary Syndromes: Results from the Platelet Inhibition and Patient Outcomes Study

Letter by Damman et al regarding articles, "Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)" and "American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: Observations From the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)”

Damman, Peter; de Winter, Robbert J; Wallentin, Lars; Fox, Keith A

Ingår i Circulation, 2012

• DOI för Letter by Damman et al regarding articles, "Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)" and "American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: Observations From the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)”

Usefulness of biomarkers for prognostication of outcome with early invasive or noninvasive treatment in non-st-elevation acute coronary syndromes - a substudy from the prospective randomized platelet inhibition and patient outcomes (PLATO) trial

Wallentin, Lars; James, Stefan; Giannitsis, Evangelos; Katus, Hugo et al.

Ingår i Journal of the American College of Cardiology, 2012

• DOI för Usefulness of biomarkers for prognostication of outcome with early invasive or noninvasive treatment in non-st-elevation acute coronary syndromes - a substudy from the prospective randomized platelet inhibition and patient outcomes (PLATO) trial

Levels of GDF-15 increase over time in an elderly population and are a strong predictor of all-cause mortality

Eggers, Kai M.; Kempf, T.; Wallentin, Lars; Wollert, K. C. et al.

Ingår i European Heart Journal, s. 947-947, 2012

• DOI för Levels of GDF-15 increase over time in an elderly population and are a strong predictor of all-cause mortality

Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients: Results from the PLATelet inhibition and patient Outcomes (PLATO) study

Åkerblom, Axel; Wallentin, Lars; Siegbahn, Agneta; Becker, R. C. et al.

Ingår i American Heart Journal, s. 728-734, 2012

• DOI för Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients: Results from the PLATelet inhibition and patient Outcomes (PLATO) study

ST Elevation Acute Coronary Syndromes in PLATO: Insights from the ECG Substudy

Armstrong, Paul W; Siha, Hany; Fu, Yuling; Westerhout, Cynthia M et al.

Ingår i Circulation, s. 514-521, 2012

• DOI för ST Elevation Acute Coronary Syndromes in PLATO: Insights from the ECG Substudy

Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects

Eggers, Kai M; Kempf, Tibor; Lind, Lars; Sundström, Johan et al.

Ingår i Scandinavian Journal of Clinical and Laboratory Investigation, s. 45-51, 2012

• DOI för Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects

Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy

Siegbahn, Agneta; Christersson, Christina; Schollin, M.; Alexander, J. H. et al.

Ingår i European Heart Journal, s. 51-51, 2012

• DOI för Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy

Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

Hohnloser, Stefan H.; Oldgren, Jonas; Yang, Sean; Wallentin, Lars et al.

Ingår i Circulation, s. 669-676, 2012

• DOI för Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Outcomes With Clopidogrel and Ticagrelor

Goodman, Shaun G.; Clare, Robert; Pieper, Karen S.; Nicolau, Jose C. et al.

Ingår i Circulation, s. 978-986, 2012

• DOI för Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Outcomes With Clopidogrel and Ticagrelor

Apixaban versus Warfarin in Atrial Fibrillation REPLY

Granger, Christopher B.; Hanna, Michael; Wallentin, Lars

Ingår i New England Journal of Medicine, s. 89-89, 2012

• DOI för Apixaban versus Warfarin in Atrial Fibrillation REPLY

Greater efficacy of ticagrelor compared to clopidogrel in acute coronary syndrome is not driven by outcomes in poor metabolizers of clopidogrel

Wallentin, Lars; James, Stefan; Storey, Robert; Barratt, Bryan et al.

Ingår i Journal of the American College of Cardiology, 2012

• DOI för Greater efficacy of ticagrelor compared to clopidogrel in acute coronary syndrome is not driven by outcomes in poor metabolizers of clopidogrel

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: reply to a rebuttal

Liesenfeld, K. -H; Lehr, T.; Dansirikul, C.; Reilly, P. A. et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 502-504, 2012

• DOI för Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: reply to a rebuttal

Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial

Van Spall, Harriette G. C.; Wallentin, Lars; Yusuf, Salim; Eikelboom, John W. et al.

Ingår i Circulation, s. 2309-2316, 2012

• DOI för Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial

Effect of Ticagrelor on the Outcomes of Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From The PLATelet inhibition and patient Outcomes (PLATO) trial

Brilakis, Emmanouil; Held, Claes; Meier, Bernhard; Cools, Frank et al.

Ingår i Journal of the American College of Cardiology, 2012

• DOI för Effect of Ticagrelor on the Outcomes of Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From The PLATelet inhibition and patient Outcomes (PLATO) trial

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial

Lopes, Renato D.; Al-Khatib, Sana M.; Wallentin, Lars; Yang, Hongqiu et al.

Ingår i The Lancet, s. 1749-1758, 2012

• DOI för Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial

Efficacy and Safety of Dabigatran Versus Warfarin in Patients with Atrial Fibrillation: Analysis in Asian Population in RE-LY Trial

Hori, M.; Connolly, S. J.; Zhu, J.; Liu, L. S. et al.

Ingår i Cerebrovascular Diseases, s. 9-9, 2012

• DOI för Efficacy and Safety of Dabigatran Versus Warfarin in Patients with Atrial Fibrillation: Analysis in Asian Population in RE-LY Trial

Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

Cornel, Jan H.; Becker, Richard C.; Goodman, Shaun G.; Husted, Steen et al.

Ingår i American Heart Journal, s. 334-342, 2012

• DOI för Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

NT-proBNP for risk stratification in atrial fibrillation during treatment with apixaban or warfarin

Wallentin, Lars C.; Christersson, Christina; Siegbahn, Agneta; Schollin, M. et al.

Ingår i European Heart Journal, s. 51-51, 2012

• DOI för NT-proBNP for risk stratification in atrial fibrillation during treatment with apixaban or warfarin

Reply to Letters Regarding Article: "Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation : An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial"

Eikelboom, John W.; Connolly, Stuart J.; Healey, Jeff S.; Yang, Sean et al.

Ingår i Circulation, 2012

• DOI för Reply to Letters Regarding Article: "Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation : An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial"

Effect of apixaban on all-cause mortality in atrial fibrillation: an imputed placebo analysis

McMurray, J. J. V.; Connolly, S. J.; Hart, R.; Flaker, G. et al.

Ingår i European Heart Journal, s. 52-52, 2012

• DOI för Effect of apixaban on all-cause mortality in atrial fibrillation: an imputed placebo analysis

High sensitivity troponin-T for risk stratification in atrial fibrillation during treatment with apixaban or warfarin

Wallentin, Lars C.; Christersson, Christina; Siegbahn, Agneta; Schollin, M. et al.

Ingår i European Heart Journal, s. 53-53, 2012

• DOI för High sensitivity troponin-T for risk stratification in atrial fibrillation during treatment with apixaban or warfarin

Serial cystatin C measurements and changes in glomerular filtration rate as predictors for death or myocardial infarction in ACS patients

Åkerblom, Axel; Wallentin, Lars; Siegbahn, Agneta; Becker, R. C. et al.

Ingår i European Heart Journal, s. 135-135, 2012

• DOI för Serial cystatin C measurements and changes in glomerular filtration rate as predictors for death or myocardial infarction in ACS patients

Impact of omeprazole (OME), esomeprazole (ESO) plus /- acetylsalicylic acid (ASA) and lansoprazole (LAN) on the pharmacodynamics (PD) and pharmacokinetics (PK) of clopidogrel in healthy volunteers

Andersson, T.; Nagy, P.; Niazi, M.; Nylander, S. et al.

Ingår i European Heart Journal, s. 343-343, 2012

• DOI för Impact of omeprazole (OME), esomeprazole (ESO) plus /- acetylsalicylic acid (ASA) and lansoprazole (LAN) on the pharmacodynamics (PD) and pharmacokinetics (PK) of clopidogrel in healthy volunteers

Apixaban after acute coronary syndrome in patients with heart failure: insights from the APPRAISE-2 trial

Cornel, J.; James, Stefan; Lopes, R. D.; Mohan, P. et al.

Ingår i European Heart Journal, s. 335-336, 2012

• DOI för Apixaban after acute coronary syndrome in patients with heart failure: insights from the APPRAISE-2 trial

Clinical characteristics associated with major bleeding in NSTE ACS and the relationship between bleeding risk, ischemic events, and the vorapaxar effect: analysis from the TRACER trial

Tricoci, P.; Huang, Z.; White, H. D.; Van De Werf, F. et al.

Ingår i European Heart Journal, s. 322-322, 2012

• DOI för Clinical characteristics associated with major bleeding in NSTE ACS and the relationship between bleeding risk, ischemic events, and the vorapaxar effect: analysis from the TRACER trial

Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial

McMurray, J. J. V.; Lewis, B.; Ezekowitz, J.; Gersh, B. et al.

Ingår i European Heart Journal, s. 519-519, 2012

• DOI för Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial

Apixaban and warfarin are associated with a low risk of stroke following cardioversion for atrial fibrillation: results from the ARISTOTLE Trial

Flaker, G.; Lopes, R.; Al-Khatib, S.; Hermosillo, A. et al.

Ingår i European Heart Journal, s. 686-686, 2012

• DOI för Apixaban and warfarin are associated with a low risk of stroke following cardioversion for atrial fibrillation: results from the ARISTOTLE Trial

Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial

Granger, C. B.; Alexander, J. H.; Hanna, M.; Wang, J. et al.

Ingår i European Heart Journal, s. 685-686, 2012

• DOI för Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial

Increased levels of D-dimer in atrial fibrillation identify patients with higher risk of thromboembolic events and death

Christersson, Christina; Schollin, M.; Alexander, J. H.; Bersh, B. J. et al.

Ingår i European Heart Journal, s. 969-969, 2012

• DOI för Increased levels of D-dimer in atrial fibrillation identify patients with higher risk of thromboembolic events and death

Predictors of low physical activity in patients with stable coronary heart disease in the global STABILITY study

Stewart, R. A. H.; Held, Claes; Brown, R.; Vedin, O. et al.

Ingår i European Heart Journal, s. 953-953, 2012

• DOI för Predictors of low physical activity in patients with stable coronary heart disease in the global STABILITY study

Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial

Husted, Steen; James, Stefan; Becker, Richard C.; Horrow, Jay et al.

Ingår i Circulation. Cardiovascular Quality and Outcomes, s. 680-688, 2012

• DOI för Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial

Healey, Jeff S.; Eikelboom, John; Douketis, James; Wallentin, Lars et al.

Ingår i Circulation, s. 343-348, 2012

• DOI för Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial

Daylight saving time shifts and incidence of acute myocardial infarction: Swedish Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA)

Janszky, Imre; Ahnve, Staffan; Ljung, Rickard; Mukamal, Kenneth J. et al.

Ingår i Sleep Medicine, s. 237-242, 2012

• DOI för Daylight saving time shifts and incidence of acute myocardial infarction: Swedish Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA)

Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery

Varenhorst, Christoph; Alström, Ulrica; Scirica, Benjamin M.; Hogue, Charles W. et al.

Ingår i Journal of the American College of Cardiology, s. 1623-1630, 2012

• DOI för Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery

Response to Letter Regarding Article, "Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO"

Goodman, Shaun G.; Clare, Robert; Pieper, Karen S.; Mahaffey, Kenneth W. et al.

Ingår i Circulation, 2012

• DOI för Response to Letter Regarding Article, "Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO"

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

Easton, J. Donald; Lopes, Renato D.; Bahit, M. Cecilia; Wojdyla, Daniel M. et al.

Ingår i Lancet Neurology, s. 503-511, 2012

• DOI för Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial

Hart, Robert G.; Diener, Hans-Christoph; Yang, Sean; Connolly, Stuart J. et al.

Ingår i Stroke, s. 1511-1517, 2012

• DOI för Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial

Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial

Siha, Hany; Das, Debraj; Fu, Yuling; Zheng, Yinggan et al.

Ingår i CMJA. Canadian Medical Association Journal. Onlineutg. Med tittel, s. 1135-1142, 2012

• DOI för Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial

Third universal definition of myocardial infarction

Thygesen, Kristian; Alpert, Joseph S; Jaffe, Allan S; Simoons, Maarten L et al.

Ingår i Circulation, s. 2020-2035, 2012

• DOI för Third universal definition of myocardial infarction

Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

Hohnloser, Stefan H.; Hijazi, Ziad; Thomas, Laine; Alexander, John H. et al.

Ingår i European Heart Journal, s. 2821-2830, 2012

• DOI för Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

Riks-HIA ska ta fram nytt index för områden med förbättringsutrymme

Jernberg, Tomas; Bergström, Olle; Held, Claes; Johanson, Per et al.

Ingår i Läkartidningen, s. 672-673, 2012

Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study

Flaker, Greg; Ezekowitz, Michael; Yusuf, Salim; Wallentin, Lars et al.

Ingår i Journal of the American College of Cardiology, s. 854-855, 2012

• DOI för Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study

Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years: Results of the Rely-Able Double-Blind Randomized Trial

Connolly, Stuart J.; Reilly, Paul A.; Pogue, Janice; Eikelboom, John et al.

Ingår i Circulation, s. 2793-2793, 2012

Management and Outcomes of Major Bleeding On Dabigatran or Warfarin

Majeed, Ammar; Hwang, Hun-Gyu; Brueckmann, Martina; Connolly, Stuart et al.

Ingår i Blood, s. 19, 2012

Third universal definition of myocardial infarction

Thygesen, Kristian; Alpert, Joseph S; Jaffe, Allan S; Simoons, Maarten L et al.

Ingår i Journal of the American College of Cardiology, s. 1581-1598, 2012

• DOI för Third universal definition of myocardial infarction

Third universal definition of myocardial infarction

Thygesen, Kristian; Alpert, Joseph S; Jaffe, Allan S; Simoons, Maarten L et al.

Ingår i European Heart Journal, s. 2551-2567, 2012

• DOI för Third universal definition of myocardial infarction

Timing of Angiography With a Routine Invasive Strategy and Long-Term Outcomes in Non-ST-Segment Elevation Acute Coronary Syndrome: A Collaborative Analysis of Individual Patient Data From the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) Trials

Damman, Peter; van Geloven, Nan; Wallentin, Lars; Lagerqvist, Bo et al.

Ingår i JACC: Cardiovascular Interventions, s. 191-199, 2012

• DOI för Timing of Angiography With a Routine Invasive Strategy and Long-Term Outcomes in Non-ST-Segment Elevation Acute Coronary Syndrome: A Collaborative Analysis of Individual Patient Data From the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) Trials

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial

Becker, Richard C; Bassand, Jean Pierre; Budaj, Andrzej; Wojdyla, Daniel M et al.

Ingår i European Heart Journal, s. 2933-2944, 2011

• DOI för Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial

Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy)

Storey, Robert F; Becker, Richard C; Harrington, Robert A; Husted, Steen et al.

Ingår i American Journal of Cardiology, s. 1542-1546, 2011

• DOI för Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy)

Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes

Storey, Robert F; Becker, Richard C; Harrington, Robert A; Husted, Steen et al.

Ingår i European Heart Journal, s. 2945-2953, 2011

• DOI för Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes